



See a Social Security Number? Say Something!  
Report Privacy Problems to <https://public.resource.org/privacy>  
Or call the IRS Identity Theft Hotline at 1-800-908-4490















**1** Briefly describe the organization's mission

See Schedule O

Form **990** (2009)

Part IV Checklist of Required Schedules

		Yes	No
1	Is the organization described in section 501(c)(3) or 4947(a)(1) (other than a private foundation)? If "Yes," complete Schedule A 	1	Yes
2	Is the organization required to complete Schedule B, Schedule of Contributors? 	2	Yes
3	Did the organization engage in direct or indirect political campaign activities on behalf of or in opposition to candidates for public office? If "Yes," complete Schedule C, Part I	3	No
4	<b>Section 501(c)(3) organizations.</b> Did the organization engage in lobbying activities? If "Yes," complete Schedule C, Part II	4	No
5	<b>Section 501(c)(4), 501(c)(5), and 501(c)(6) organizations.</b> Is the organization subject to the section 6033(e) notice and reporting requirement and proxy tax? If "Yes," complete Schedule C, Part III	5	
6	Did the organization maintain any donor advised funds or any similar funds or accounts where donors have the right to provide advice on the distribution or investment of amounts in such funds or accounts? If "Yes," complete Schedule D, Part I 	6	No
7	Did the organization receive or hold a conservation easement, including easements to preserve open space, the environment, historic land areas or historic structures? If "Yes," complete Schedule D, Part II 	7	No
8	Did the organization maintain collections of works of art, historical treasures, or other similar assets? If "Yes," complete Schedule D, Part III 	8	No
9	Did the organization report an amount in Part X, line 21, serve as a custodian for amounts not listed in Part X, or provide credit counseling, debt management, credit repair, or debt negotiation services? If "Yes," complete Schedule D, Part IV 	9	No
10	Did the organization, directly or through a related organization, hold assets in term, permanent, or quasi-endowments? If "Yes," complete Schedule D, Part V 	10	No
11	Is the organization's answer to any of the following questions "Yes"? If so, complete Schedule D, Parts VI, VII, VIII, IX, or X as applicable. 	11	Yes
	• Did the organization report an amount for land, buildings, and equipment in Part X, line 10? If "Yes," complete Schedule D, Part VI.		
	• Did the organization report an amount for investments—other securities in Part X, line 12 that is 5% or more of its total assets reported in Part X, line 16? If "Yes," complete Schedule D, Part VII.		
	• Did the organization report an amount for investments—program related in Part X, line 13 that is 5% or more of its total assets reported in Part X, line 16? If "Yes," complete Schedule D, Part VIII.		
	• Did the organization report an amount for other assets in Part X, line 15 that is 5% or more of its total assets reported in Part X, line 16? If "Yes," complete Schedule D, Part IX.		
	• Did the organization report an amount for other liabilities in Part X, line 25? If "Yes," complete Schedule D, Part X.		
	• Did the organization's separate or consolidated financial statements for the tax year include a footnote that addresses the organization's liability for uncertain tax positions under FIN 48? If "Yes," complete Schedule D, Part X.		
12	Did the organization obtain separate, independent audited financial statements for the tax year? If "Yes," complete Schedule D, Parts XI, XII, and XIII 	12	No
12A	Was the organization included in consolidated, independent audited financial statements for the tax year?	Yes	No
	If "Yes," completing Schedule D, Parts XI, XII, and XIII is optional 	12A	Yes
13	Is the organization a school described in section 170(b)(1)(A)(ii)? If "Yes," complete Schedule E	13	No
14a	Did the organization maintain an office, employees, or agents outside of the United States?	14a	No
14b	Did the organization have aggregate revenues or expenses of more than \$10,000 from grantmaking, fundraising, business, and program service activities outside the United States? If "Yes," complete Schedule F, Part I	14b	No
15	Did the organization report on Part IX, column (A), line 3, more than \$5,000 of grants or assistance to any organization or entity located outside the U S ? If "Yes," complete Schedule F, Part II	15	No
16	Did the organization report on Part IX, column (A), line 3, more than \$5,000 of aggregate grants or assistance to individuals located outside the U S ? If "Yes," complete Schedule F, Part III	16	No
17	Did the organization report a total of more than \$15,000, of expenses for professional fundraising services on Part IX, column (A), lines 6 and 11e? If "Yes," complete Schedule G, Part I	17	No
18	Did the organization report more than \$15,000 total of fundraising event gross income and contributions on Part VIII, lines 1c and 8a? If "Yes," complete Schedule G, Part II	18	No
19	Did the organization report more than \$15,000 of gross income from gaming activities on Part VIII, line 9a? If "Yes," complete Schedule G, Part III	19	No
20	Did the organization operate one or more hospitals? If "Yes," complete Schedule H	20	No

Part IV

Checklist of Required Schedules (continued)

21	Did the organization report more than \$5,000 of grants and other assistance to governments and organizations in the United States on Part IX, column (A), line 1? <i>If "Yes," complete Schedule I, Parts I and II</i> . . . . .	21		No
22	Did the organization report more than \$5,000 of grants and other assistance to individuals in the United States on Part IX, column (A), line 2? <i>If "Yes," complete Schedule I, Parts I and III</i> . . . . .	22	Yes	
23	Did the organization answer "Yes" to Part VII, Section A, questions 3, 4, or 5, about compensation of the organization's current and former officers, directors, trustees, key employees, and highest compensated employees? <i>If "Yes," complete Schedule J</i> . . . . .	23	Yes	
24a	Did the organization have a tax-exempt bond issue with an outstanding principal amount of more than \$100,000 as of the last day of the year, that was issued after December 31, 2002? <i>If "Yes," answer questions 24b–24d and complete Schedule K. If "No," go to line 25</i> . . . . .	24a		No
b	Did the organization invest any proceeds of tax-exempt bonds beyond a temporary period exception? . . . .	24b		
c	Did the organization maintain an escrow account other than a refunding escrow at any time during the year to defease any tax-exempt bonds? . . . . .	24c		
d	Did the organization act as an "on behalf of" issuer for bonds outstanding at any time during the year? . . . .	24d		
25a	<b>Section 501(c)(3) and 501(c)(4) organizations.</b> Did the organization engage in an excess benefit transaction with a disqualified person during the year? <i>If "Yes," complete Schedule L, Part I</i> . . . . .	25a		No
b	Is the organization aware that it engaged in an excess benefit transaction with a disqualified person in a prior year, and that the transaction has not been reported on any of the organization's prior Forms 990 or 990-EZ? <i>If "Yes," complete Schedule L, Part I</i> . . . . .	25b		No
26	Was a loan to or by a current or former officer, director, trustee, key employee, highly compensated employee, or disqualified person outstanding as of the end of the organization's tax year? <i>If "Yes," complete Schedule L, Part II</i> . . . . .	26		No
27	Did the organization provide a grant or other assistance to an officer, director, trustee, key employee, substantial contributor, or a grant selection committee member, or to a person related to such an individual? <i>If "Yes," complete Schedule L, Part III</i> . . . . .	27		No
28	Was the organization a party to a business transaction with one of the following parties? (see Schedule L, Part IV instructions for applicable filing thresholds, conditions, and exceptions)			
a	A current or former officer, director, trustee, or key employee? <i>If "Yes," complete Schedule L, Part IV</i> . . . . .	28a		No
b	A family member of a current or former officer, director, trustee, or key employee? <i>If "Yes," complete Schedule L, Part IV</i> . . . . .	28b		No
c	An entity of which a current or former officer, director, trustee, or key employee of the organization (or a family member) was an officer, director, trustee, or owner? <i>If "Yes," complete Schedule L, Part IV</i> . . . . .	28c	Yes	
29	Did the organization receive more than \$25,000 in non-cash contributions? <i>If "Yes," complete Schedule M</i> . . . . .	29	Yes	
30	Did the organization receive contributions of art, historical treasures, or other similar assets, or qualified conservation contributions? <i>If "Yes," complete Schedule M</i> . . . . .	30		No
31	Did the organization liquidate, terminate, or dissolve and cease operations? <i>If "Yes," complete Schedule N, Part I</i> . . . . .	31		No
32	Did the organization sell, exchange, dispose of, or transfer more than 25% of its net assets? <i>If "Yes," complete Schedule N, Part II</i> . . . . .	32		No
33	Did the organization own 100% of an entity disregarded as separate from the organization under Regulations sections 301.7701-2 and 301.7701-3? <i>If "Yes," complete Schedule R, Part I</i> . . . . .	33		No
34	Was the organization related to any tax-exempt or taxable entity? <i>If "Yes," complete Schedule R, Parts II, III, IV, and V, line 1</i> . . . . .	34	Yes	
35	Is any related organization a controlled entity within the meaning of section 512(b)(13)? <i>If "Yes," complete Schedule R, Part V, line 2</i> . . . . .	35	Yes	
36	<b>Section 501(c)(3) organizations.</b> Did the organization make any transfers to an exempt non-charitable related organization? <i>If "Yes," complete Schedule R, Part V, line 2</i> . . . . .	36		No
37	Did the organization conduct more than 5% of its activities through an entity that is not a related organization and that is treated as a partnership for federal income tax purposes? <i>If "Yes," complete Schedule R, Part VI</i> . . . . .	37		No
38	Did the organization complete Schedule O and provide explanations in Schedule O for Part VI, lines 11 and 19? <b>Note.</b> All Form 990 filers are required to complete Schedule O . . . . .	38	Yes	

Part V

Statements Regarding Other IRS Filings and Tax Compliance

			Yes	No	
1a	Enter the number reported in Box 3 of Form 1096, <i>Annual Summary and Transmittal of U.S. Information Returns</i> . Enter -0- if not applicable . . . . .	1a	32		
	b	Enter the number of Forms W-2G included in line 1a. Enter -0- if not applicable	1b		0
c Did the organization comply with backup withholding rules for reportable payments to vendors and reportable gaming (gambling) winnings to prize winners? . . . . .			1c	Yes	
2a	Enter the number of employees reported on Form W-3, <i>Transmittal of Wage and Tax Statements</i> filed for the calendar year ending with or within the year covered by this return . . . . .	2a	379		
	b If at least one is reported on line 2a, did the organization file all required federal employment tax returns? <b>Note:</b> If the sum of lines 1a and 2a is greater than 250, you may be required to e-file this return (see instructions)				2b
3a	Did the organization have unrelated business gross income of \$1,000 or more during the year covered by this return? . . . . .			3a	No
b If "Yes," has it filed a Form 990-T for this year? If "No," provide an explanation in Schedule O . . . . .			3b		
4a	At any time during the calendar year, did the organization have an interest in, or a signature or other authority over, a financial account in a foreign country (such as a bank account, securities account, or other financial account)? . . . . .			4a	No
	b If "Yes," enter the name of the foreign country: <input type="text"/> See the instructions for exceptions and filing requirements for Form TD F 90-22.1, Report of Foreign Bank and Financial Accounts				
5a	Was the organization a party to a prohibited tax shelter transaction at any time during the tax year? . . .			5a	No
b Did any taxable party notify the organization that it was or is a party to a prohibited tax shelter transaction?			5b	No	
c If "Yes" to line 5a or 5b, did the organization file Form 8886-T, Disclosure by Tax-Exempt Entity Regarding Prohibited Tax Shelter Transaction? . . . . .			5c		
6a	Does the organization have annual gross receipts that are normally greater than \$100,000, and did the organization solicit any contributions that were not tax deductible? . . . . .			6a	No
b If "Yes," did the organization include with every solicitation an express statement that such contributions or gifts were not tax deductible? . . . . .			6b		
7 Organizations that may receive deductible contributions under section 170(c).					
a Did the organization receive a payment in excess of \$75 made partly as a contribution and partly for goods and services provided to the payor? . . . . .			7a	No	
b If "Yes," did the organization notify the donor of the value of the goods or services provided? . . . . .			7b		
c Did the organization sell, exchange, or otherwise dispose of tangible personal property for which it was required to file Form 8282? . . . . .			7c	No	
d If "Yes," indicate the number of Forms 8282 filed during the year . . . . .			7d		
e Did the organization, during the year, receive any funds, directly or indirectly, to pay premiums on a personal benefit contract? . . . . .			7e	No	
f Did the organization, during the year, pay premiums, directly or indirectly, on a personal benefit contract? . . .			7f	No	
g For all contributions of qualified intellectual property, did the organization file Form 8899 as required? . . .			7g		
h For contributions of cars, boats, airplanes, and other vehicles, did the organization file a Form 1098-C as required? . . . . .			7h		
8 Sponsoring organizations maintaining donor advised funds and section 509(a)(3) supporting organizations. Did the supporting organization, or a donor advised fund maintained by a sponsoring organization, have excess business holdings at any time during the year? . . . . .			8		
9 Sponsoring organizations maintaining donor advised funds.					
a Did the organization make any taxable distributions under section 4966? . . . . .			9a		
b Did the organization make a distribution to a donor, donor advisor, or related person? . . . . .			9b		
10 Section 501(c)(7) organizations. Enter					
a Initiation fees and capital contributions included on Part VIII, line 12 . . . . .		10a			
b Gross receipts, included on Form 990, Part VIII, line 12, for public use of club facilities		10b			
11 Section 501(c)(12) organizations. Enter					
a Gross income from members or shareholders . . . . .		11a			
b Gross income from other sources (Do not net amounts due or paid to other sources against amounts due or received from them) . . . . .		11b			
12a Section 4947(a)(1) non-exempt charitable trusts. Is the organization filing Form 990 in lieu of Form 1041?			12a		
b If "Yes," enter the amount of tax-exempt interest received or accrued during the year			12b		

Part VI

Governance, Management, and Disclosure

For each "Yes" response to lines 2 through 7b below, and for a "No" response to lines 8a, 8b, or 10b below, describe the circumstances, processes, or changes in Schedule O. See instructions.

Section A. Governing Body and Management

			Yes	No
1a	Enter the number of voting members of the governing body . . .	1a	6	
b	Enter the number of voting members that are independent . . .	1b	0	
2	Did any officer, director, trustee, or key employee have a family relationship or a business relationship with any other officer, director, trustee, or key employee? . . . . .	2	Yes	
3	Did the organization delegate control over management duties customarily performed by or under the direct supervision of officers, directors or trustees, or key employees to a management company or other person? . . .	3		No
4	Did the organization make any significant changes to its organizational documents since the prior Form 990 was filed?	4		No
5	Did the organization become aware during the year of a material diversion of the organization's assets? . . .	5		No
6	Does the organization have members or stockholders? . . . . .	6		No
7a	Does the organization have members, stockholders, or other persons who may elect one or more members of the governing body? . . . . .	7a		No
b	Are any decisions of the governing body subject to approval by members, stockholders, or other persons? . . .	7b		No
8	Did the organization contemporaneously document the meetings held or written actions undertaken during the year by the following			
a	The governing body? . . . . .	8a	Yes	
b	Each committee with authority to act on behalf of the governing body? . . . . .	8b	Yes	
9	Is there any officer, director, trustee, or key employee listed in Part VII, Section A, who cannot be reached at the organization's mailing address? If "Yes," provide the names and addresses in Schedule O . . . . .	9		No

Section B. Policies

(This Section B requests information about policies not required by the Internal Revenue Code.)

			Yes	No
10a	Does the organization have local chapters, branches, or affiliates? . . . . .	10a		No
b	If "Yes," does the organization have written policies and procedures governing the activities of such chapters, affiliates, and branches to ensure their operations are consistent with those of the organization? . . . . .	10b		
11	Has the organization provided a copy of this Form 990 to all members of its governing body before filing the form?	11	Yes	
11A	Describe in Schedule O the process, if any, used by the organization to review the Form 990 . . . . .			
12a	Does the organization have a written conflict of interest policy? If "No," go to line 13 . . . . .	12a	Yes	
b	Are officers, directors or trustees, and key employees required to disclose annually interests that could give rise to conflicts? . . . . .	12b	Yes	
c	Does the organization regularly and consistently monitor and enforce compliance with the policy? If "Yes," describe in Schedule O how this is done . . . . .	12c	Yes	
13	Does the organization have a written whistleblower policy? . . . . .	13	Yes	
14	Does the organization have a written document retention and destruction policy? . . . . .	14	Yes	
15	Did the process for determining compensation of the following persons include a review and approval by independent persons, comparability data, and contemporaneous substantiation of the deliberation and decision?			
a	The organization's CEO, Executive Director, or top management official . . . . .	15a	Yes	
b	Other officers or key employees of the organization . . . . .	15b	Yes	
	If "Yes" to line a or b, describe the process in Schedule O (See instructions )			
16a	Did the organization invest in, contribute assets to, or participate in a joint venture or similar arrangement with a taxable entity during the year? . . . . .	16a		No
b	If "Yes," has the organization adopted a written policy or procedure requiring the organization to evaluate its participation in joint venture arrangements under applicable federal tax law, and taken steps to safeguard the organization's exempt status with respect to such arrangements? . . . . .	16b		

Section C. Disclosure

17	List the States with which a copy of this Form 990 is required to be filed▶MA
18	Section 6104 requires an organization to make its Form 1023 (or 1024 if applicable), 990, and 990-T (501(c) (3)s only) available for public inspection. Indicate how you make these available. Check all that apply. <input type="checkbox"/> Own website <input type="checkbox"/> Another's website <input checked="" type="checkbox"/> Upon request
19	Describe in Schedule O whether (and if so, how), the organization makes its governing documents, conflict of interest policy, and financial statements available to the public. See Additional Data Table.
20	State the name, physical address, and telephone number of the person who possesses the books and records of the organization ▶ J SCOTT PETTET 1000 E 50TH STREET kansas city, MO 64110 (816) 926-4000

Part VII

Compensation of Officers, Directors, Trustees, Key Employees, Highest Compensated Employees, and Independent Contractors

Section A. Officers, Directors, Trustees, Key Employees, and Highest Compensated Employees

1a Complete this table for all persons required to be listed Report compensation for the calendar year ending with or within the organization’s tax year Use Schedule J-2 if additional space is needed

- List all of the organization’s **current** officers, directors, trustees (whether individuals or organizations), regardless of amount of compensation, and **current** key employees Enter -0- in columns (D), (E), and (F) if no compensation was paid
- List all of the organization’s **current** key employees See instructions for definition of "key employee "
- List the organization’s five **current** highest compensated employees (other than an officer, director, trustee or key employee) who received reportable compensation (Box 5 of Form W-2 and/or Box 7 of Form 1099-MISC) of more than \$100,000 from the organization and any related organizations
- List all of the organization’s **former** officers, key employees, or highest compensated employees who received more than \$100,000 of reportable compensation from the organization and any related organizations
- List all of the organization’s **former directors or trustees** that received, in the capacity as a former director or trustee of the organization, more than \$10,000 of reportable compensation from the organization and any related organizations

List persons in the following order individual trustees or directors , institutional trustees , officers , key employees , highest compensated employees , and former such persons

☐ Check this box if the organization did not compensate any current or former officer, director, trustee or key employee

(A) Name and Title	(B) Average hours per week	(C) Position (check all that apply)						(D) Reportable compensation from the organization (W-2/1099-MISC)	(E) Reportable compensation from related organizations (W-2/1099-MISC)	(F) Estimated amount of other compensation from the organization and related organizations
		Individual trustee or director	Institutional Trustee	Officer	Key employee	Highest compensated employee	Former			
JAMES ESTOWERS JR Director	2 0	X						0	0	0
RICHARD WBROWN Director/CHAIR - see sch o	2 0	X		X				0	1,580,754	47,202
DAVID AWELTE DIRECTOR/SECRETARY See Sch O	2 0	X		X				0	841,856	51,335
RODERICK L STURGEON DIRECTOR - SEE SCHEDULE O	2 0	X						0	1,053,247	50,802
WILLIAM B NEAVES DIRECTOR/PRESIDENT/CEO	40 0	X		X				1,110,894	0	47,969
DAVID M CHAO DIRECTOR/PRESIDENT - see sch o	40 0	X		X				400,063	226,959	38,193
ROBERT E KRUMLAUF SCIENTIFIC DIRECTOR	40 0				X			430,750	0	50,129
RONALD C CONAWAY INVESTIGATOR	40 0					X		236,418	0	36,684
JOAN W CONAWAY INVESTIGATOR	40 0					X		235,846	0	45,501
JERRY L WORKMAN INVESTIGATOR	40 0					X		231,560	0	41,139
R SCOTT HAWLEY INVESTIGATOR	40 0					X		225,946	0	53,121
ARCADY R MUSHEGIAN DIR OF BIOINFORMATICS CENTER	40 0					X		209,552	0	46,117



## Part VII

2 Total number of individuals (including but not limited to those listed above) who received more than \$100,000 in reportable compensation from the organization: 32

## Section B. Independent Contractors

2	Total number of independent contractors (including but not limited to those listed above) who received more than \$100,000 in compensation from the organization ▶1	
---	---	--

Part VIII

Statement of Revenue

				(A) Total revenue	(B) Related or exempt function revenue	(C) Unrelated business revenue	(D) Revenue excluded from tax under sections 512, 513, or 514
Contributions, gifts, grants and other similar amounts	1a	Federated campaigns . . .	1a				
	b	Membership dues . . . . .	1b				
	c	Fundraising events . . . . .	1c				
	d	Related organizations . . . .	1d	253,801			
	e	Government grants (contributions)	1e	5,400,207			
	f	All other contributions, gifts, grants, and similar amounts not included above	1f	938,976			
	g	Noncash contributions included in lines 1a-1f \$ 272,306					
	h	Total. Add lines 1a-1f . . . . .		6,592,984			
Program Service Revenue	2a	COLLABORATION FEE FROM HHM1,501(C) (3)	Business Code	900,099	224,514	224,514	
	b						
	c						
	d						
	e						
	f	All other program service revenue					
	g	Total. Add lines 2a-2f . . . . .		224,514			
	Other Revenue	3	Investment income (including dividends, interest and other similar amounts) . . . . .		2,995,914		
4		Income from investment of tax-exempt bond proceeds . .		0			
5		Royalties . . . . .		145,263			145,263
6a		Gross Rents	(i) Real	415,575			
b		Less rental expenses	(ii) Personal	415,575			
c		Rental income or (loss)					
d		Net rental income or (loss) . . . . .					
7a		Gross amount from sales of assets other than inventory	(i) Securities	82,964,169			
b		Less cost or other basis and sales expenses	(ii) Other	166,563			
c		Gain or (loss)		82,083,964			
d		Net gain or (loss) . . . . .		880,205			
8a		Gross income from fundraising events (not including \$ _____ of contributions reported on line 1c) See Part IV, line 18 . . . . .					
b		Less direct expenses . . . . .					
c		Net income or (loss) from fundraising events . .					
9a		Gross income from gaming activities See Part IV, line 19 . . . . .					
b		Less direct expenses . . . . .					
c		Net income or (loss) from gaming activities . .					
10a		Gross sales of inventory, less returns and allowances . . . . .					
b		Less cost of goods sold . . . . .					
c		Net income or (loss) from sales of inventory . .					
		Miscellaneous Revenue	Business Code				
11a		OTHER REVENUE		900,099	19,955		19,955
b							
c							
d	All other revenue . . . . .						
e	Total. Add lines 11a-11d . . . . .			19,955			
12	Total revenue. See Instructions . . . . .			10,816,749	224,514		3,999,251

Part IX

Statement of Functional Expenses

Section 501(c)(3) and 501(c)(4) organizations must complete all columns.

All other organizations must complete column (A) but are not required to complete columns (B), (C), and (D).

Do not include amounts reported on lines 6b, 7b, 8b, 9b, and 10b of Part VIII.		(A) Total expenses	(B) Program service expenses	(C) Management and general expenses	(D) Fundraising expenses
1	Grants and other assistance to governments and organizations in the U S See Part IV, line 21	0			
2	Grants and other assistance to individuals in the U S See Part IV, line 22	1,326,774	1,326,774		
3	Grants and other assistance to governments, organizations, and individuals outside the U S See Part IV, lines 15 and 16	0			
4	Benefits paid to or for members	0			
5	Compensation of current officers, directors, trustees, and key employees . . . . .	1,944,252	1,749,827	194,425	
6	Compensation not included above, to disqualified persons (as defined under section 4958(f)(1)) and persons described in section 4958(c)(3)(B) . . . . .	0			
7	Other salaries and wages	17,775,908	15,998,317	1,777,591	
8	Pension plan contributions (include section 401(k) and section 403(b) employer contributions) . . . . .	2,609,790	2,348,811	260,979	
9	Other employee benefits . . . . .	2,598,228	2,338,405	259,823	
10	Payroll taxes . . . . .	1,294,580	1,165,122	129,458	
11	Fees for services (non-employees)				
a	Management . . . . .	0			
b	Legal . . . . .	151,620		151,620	
c	Accounting . . . . .	0			
d	Lobbying . . . . .	0			
e	Professional fundraising See Part IV, line 17 . . . . .	0			
f	Investment management fees . . . . .	0			
g	Other . . . . .	1,130,311	1,017,280	113,031	
12	Advertising and promotion . . . . .	0			
13	Office expenses . . . . .	283,798	255,418	28,380	
14	Information technology . . . . .	360,587	324,528	36,059	
15	Royalties . . . . .	24,949	22,454	2,495	
16	Occupancy . . . . .	2,111,355	1,900,220	211,135	
17	Travel . . . . .	548,397	493,557	54,840	
18	Payments of travel or entertainment expenses for any federal, state, or local public officials . . . . .	0			
19	Conferences, conventions, and meetings . . . . .	664,292	597,863	66,429	
20	Interest . . . . .	0			
21	Payments to affiliates . . . . .	0			
22	Depreciation, depletion, and amortization . . . . .	15,488,362	13,939,526	1,548,836	
23	Insurance . . . . .	0			
24	Other expenses Itemize expenses not covered above (Expenses grouped together and labeled miscellaneous may not exceed 5% of total expenses shown on line 25 below )				
a	COST-SHARING WITH RELATED ORG	16,809,457	15,128,511	1,680,946	
b	LAB SUPPLIES	6,386,139	5,747,525	638,614	
c	NON-CAPITAL EQUIPMENT	288,108	259,297	28,811	
d	SCIENTIFIC CONSULTING	233,059	209,753	23,306	
e	COLLABORATION EXPENSE	134,804	121,324	13,480	
f	All other expenses	195,351	175,816	19,535	
25	Total functional expenses. Add lines 1 through 24f	72,360,121	65,120,328	7,239,793	0
26	Joint costs. Check here <input type="checkbox"/> if following SOP 98-2 Complete this line only if the organization reported in column (B) joint costs from a combined educational campaign and fundraising solicitation				

Part X

Balance Sheet

					(A)		(B)
					Beginning of year		End of year
Assets	1	Cash—non-interest-bearing . . . . .			-49,089	1	3,699,012
	2	Savings and temporary cash investments . . . . .				2	
	3	Pledges and grants receivable, net . . . . .			588,187	3	720,639
	4	Accounts receivable, net . . . . .				4	
	5	Receivables from current and former officers, directors, trustees, key employees, and highest compensated employees. Complete Part II of Schedule L . . . . .				5	
	6	Receivables from other disqualified persons (as defined under section 4958(f)(1)) and persons described in section 4958(c)(3)(B). Complete Part II of Schedule L . . . . .				6	
	7	Notes and loans receivable, net . . . . .				7	
	8	Inventories for sale or use . . . . .			403,812	8	398,012
	9	Prepaid expenses and deferred charges . . . . .			1,248,322	9	553,403
	10a	Land, buildings, and equipment, cost or other basis. Complete Part VI of Schedule D . . . . .	10a	309,724,271			
	b	Less accumulated depreciation . . . . .	10b	107,596,364	214,695,493	10c	202,127,907
	11	Investments—publicly traded securities . . . . .			184,307,125	11	136,133,751
	12	Investments—other securities. See Part IV, line 11 . . . . .			0	12	0
	13	Investments—program-related. See Part IV, line 11 . . . . .				13	
	14	Intangible assets . . . . .				14	
	15	Other assets. See Part IV, line 11 . . . . .			232,217,052	15	222,146,556
	16	<b>Total assets.</b> Add lines 1 through 15 (must equal line 34) . . . . .			633,410,902	16	565,779,280
Liabilities	17	Accounts payable and accrued expenses . . . . .			8,448,203	17	7,131,445
	18	Grants payable . . . . .				18	
	19	Deferred revenue . . . . .				19	
	20	Tax-exempt bond liabilities . . . . .				20	
	21	Escrow or custodial account liability. Complete Part IV of Schedule D . . . . .				21	
	22	Payables to current and former officers, directors, trustees, key employees, highest compensated employees, and disqualified persons. Complete Part II of Schedule L . . . . .				22	
	23	Secured mortgages and notes payable to unrelated third parties . . . . .				23	
	24	Unsecured notes and loans payable to unrelated third parties . . . . .				24	
	25	Other liabilities. Complete Part X of Schedule D . . . . .			225,113,659	25	220,373,182
	26	<b>Total liabilities.</b> Add lines 17 through 25 . . . . .			233,561,862	26	227,504,627
Net Assets or Fund Balances	<b>Organizations that follow SFAS 117, check here</b> <input checked="" type="checkbox"/> <b>and complete lines 27 through 29, and lines 33 and 34.</b>						
	27	Unrestricted net assets . . . . .			399,849,040	27	338,274,653
	28	Temporarily restricted net assets . . . . .				28	
	29	Permanently restricted net assets . . . . .				29	
	<b>Organizations that do not follow SFAS 117, check here</b> <input type="checkbox"/> <b>and complete lines 30 through 34.</b>						
	30	Capital stock or trust principal, or current funds . . . . .				30	
	31	Paid-in or capital surplus, or land, building or equipment fund . . . . .				31	
	32	Retained earnings, endowment, accumulated income, or other funds . . . . .				32	
	33	<b>Total net assets or fund balances</b> . . . . .			399,849,040	33	338,274,653
	34	<b>Total liabilities and net assets/fund balances</b> . . . . .			633,410,902	34	565,779,280

**Part XI Financial Statements and Reporting**

	Yes	No
<b>1</b> Accounting method used to prepare the Form 990 <input type="checkbox"/> Cash <input checked="" type="checkbox"/> Accrual <input type="checkbox"/> Other _____ If the organization changed its method of accounting from a prior year or checked "Other," explain in Schedule O		
<b>2a</b> Were the organization's financial statements compiled or reviewed by an independent accountant? . . .		No
<b>b</b> Were the organization's financial statements audited by an independent accountant? . . . . .	Yes	
<b>c</b> If "Yes," to 2a or 2b, does the organization have a committee that assumes responsibility for oversight of the audit, review, or compilation of its financial statements and selection of an independent accountant? If the organization changed either its oversight process or selection process during the tax year, explain in Schedule O . . . .	Yes	
<b>d</b> If "Yes" to line 2a or 2b, check a box below to indicate whether the financial statements for the year were issued on a consolidated basis, separate basis, or both <input type="checkbox"/> Separate basis <input checked="" type="checkbox"/> Consolidated basis <input type="checkbox"/> Both consolidated and separated basis		
<b>3a</b> As a result of a federal award, was the organization required to undergo an audit or audits as set forth in the Single Audit Act and OMB Circular A-133? . . . . .	Yes	
<b>b</b> If "Yes," did the organization undergo the required audit or audits? If the organization did not undergo the required audit or audits, explain why in Schedule O and describe any steps taken to undergo such audits . . .	Yes	

SCHEDULE A

(Form 990 or 990EZ)

Department of the Treasury  
Internal Revenue Service

Public Charity Status and Public Support

Complete if the organization is a section 501(c)(3) organization or a section 4947(a)(1) nonexempt charitable trust.

▶ Attach to Form 990 or Form 990-EZ. ▶ See separate instructions.

OMB No 1545-0047

2009

Open to Public  
Inspection

Name of the organization Stowers Institute for Medical Research		Employer identification number 20-2993509
--	--	--

Part I

Reason for Public Charity Status (All organizations must complete this part.) See instructions

The organization is not a private foundation because it is (For lines 1 through 11, check only one box )

- 1

☐

A church, convention of churches, or association of churches **section 170(b)(1)(A)(i).**
- 2

☐

A school described in **section 170(b)(1)(A)(ii).** (Attach Schedule E )
- 3

☐

A hospital or a cooperative hospital service organization described in **section 170(b)(1)(A)(iii).**
- 4

☒

A medical research organization operated in conjunction with a hospital described in **section 170(b)(1)(A)(iii).** Enter the hospital's name, city, and state  
  
The Massachusetts General Hospital,  
/ ,  
Boston, MA
- 5

☐

An organization operated for the benefit of a college or university owned or operated by a governmental unit described in **section 170(b)(1)(A)(iv).** (Complete Part II )
- 6

☐

A federal, state, or local government or governmental unit described in **section 170(b)(1)(A)(v).**
- 7

☐

An organization that normally receives a substantial part of its support from a governmental unit or from the general public described in **section 170(b)(1)(A)(vi)** (Complete Part II )
- 8

☐

A community trust described in **section 170(b)(1)(A)(vi)** (Complete Part II )
- 9

☐

An organization that normally receives (1) more than 33 1/3% of its support from contributions, membership fees, and gross receipts from activities related to its exempt functions—subject to certain exceptions, and (2) no more than 33 1/3% of its support from gross investment income and unrelated business taxable income (less section 511 tax) from businesses acquired by the organization after June 30, 1975 See **section 509(a)(2).** (Complete Part III )
- 10

☐

An organization organized and operated exclusively to test for public safety See**section 509(a)(4).**
- 11

☐

An organization organized and operated exclusively for the benefit of, to perform the functions of, or to carry out the purposes of one or more publicly supported organizations described in section 509(a)(1) or section 509(a)(2) See **section 509(a)(3).** Check the box that describes the type of supporting organization and complete lines 11e through 11h  

a

☐

Type I

b

☐

Type II

c

☐

Type III - Functionally integrated

d

☐

Type III - Other

e

☐

By checking this box, I certify that the organization is not controlled directly or indirectly by one or more disqualified persons other than foundation managers and other than one or more publicly supported organizations described in section 509(a)(1) or section 509(a)(2)

f

☐

If the organization received a written determination from the IRS that it is a Type I, Type II or Type III supporting organization, check this box

g

☐

Since August 17, 2006, has the organization accepted any gift or contribution from any of the following persons?  

(i)

a person who directly or indirectly controls, either alone or together with persons described in (ii) and (iii) below, the governing body of the the supported organization?

(ii)

a family member of a person described in (i) above?

(iii)

a 35% controlled entity of a person described in (i) or (ii) above?

h

☐

Provide the following information about the supported organization(s)

(i) Name of supported organization	(ii) EIN	(iii) Type of organization (described on lines 1- 9 above or IRC section (see instructions))	(iv) Is the organization in col (i) listed in your governing document?		(v) Did you notify the organization in col (i) of your support?		(vi) Is the organization in col (i) organized in the U S ?		(vii) Amount of support?
			Yes	No	Yes	No	Yes	No	
Total									

Part II

Support Schedule for Organizations Described in IRC 170(b)(1)(A)(iv) and 170(b)(1)(A)(vi)  
(Complete only if you checked the box on line 5, 7, or 8 of Part I.)

Section A. Public Support

Calendar year (or fiscal year beginning in)	(a) 2005	(b) 2006	(c) 2007	(d) 2008	(e) 2009	(f) Total
1 Gifts, grants, contributions, and membership fees received (Do not include any "unusual grants.")						
2 Tax revenues levied for the organization's benefit and either paid to or expended on its behalf						
3 The value of services or facilities furnished by a governmental unit to the organization without charge						
4 Total. Add lines 1 through 3						
5 The portion of total contributions by each person (other than a governmental unit or publicly supported organization) included on line 1 that exceeds 2% of the amount shown on line 11, column (f)						
6 Public Support. Subtract line 5 from line 4						

Section B. Total Support

Calendar year (or fiscal year beginning in)	(a) 2005	(b) 2006	(c) 2007	(d) 2008	(e) 2009	(f) Total
7 Amounts from line 4						
8 Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources						
9 Net income from unrelated business activities, whether or not the business is regularly carried on						
10 Other income (Explain in Part IV ) Do not include gain or loss from the sale of capital assets						
11 Total support (Add lines 7 through 10)						
12 Gross receipts from related activities, etc (See instructions )					12	
13 First Five Years If the Form 990 is for the organization's first, second, third, fourth, or fifth tax year as a 501(c)(3) organization, check this box and stop here						

Section C. Computation of Public Support Percentage

14 Public Support Percentage for 2009 (line 6 column (f) divided by line 11 column (f))	14	
15 Public Support Percentage for 2008 Schedule A, Part II, line 14	15	
16a 33 1/3% support test—2009. If the organization did not check the box on line 13, and line 14 is 33 1/3% or more, check this box and stop here. The organization qualifies as a publicly supported organization		
b 33 1/3% support test—2008. If the organization did not check the box on line 13 or 16a, and line 15 is 33 1/3% or more, check this box and stop here. The organization qualifies as a publicly supported organization		
17a 10%-facts-and-circumstances test—2009. If the organization did not check a box on line 13, 16a, or 16b and line 14 is 10% or more, and if the organization meets the "facts and circumstances" test, check this box and stop here. Explain in Part IV how the organization meets the "facts and circumstances" test The organization qualifies as a publicly supported organization		
b 10%-facts-and-circumstances test—2008. If the organization did not check a box on line 13, 16a, 16b, or 17a and line 15 is 10% or more, and if the organization meets the "facts and circumstances" test, check this box and stop here. Explain in Part IV how the organization meets the "facts and circumstances" test The organization qualifies as a publicly supported organization		
18 Private Foundation If the organization did not check a box on line 13, 16a, 16b, 17a or 17b, check this box and see instructions		

Part IIISupport Schedule for Organizations Described in IRC 509(a)(2)  
(Complete only if you checked the box on line 9 of Part I.)

Section A. Public Support

Calendar year (or fiscal year beginning in)	(a) 2005	(b) 2006	(c) 2007	(d) 2008	(e) 2009	(f) Total
1Gifts, grants, contributions, and membership fees received (Do not include any "unusual grants.")						
2Gross receipts from admissions, merchandise sold or services performed, or facilities furnished in any activity that is related to the organization's tax-exempt purpose						
3Gross receipts from activities that are not an unrelated trade or business under section 513						
4Tax revenues levied for the organization's benefit and either paid to or expended on its behalf						
5The value of services or facilities furnished by a governmental unit to the organization without charge						
6Total. Add lines 1 through 5						
7aAmounts included on lines 1, 2, and 3 received from disqualified persons						
bAmounts included on lines 2 and 3 received from other than disqualified persons that exceed the greater of \$5,000 or 1% of the amount on line 13 for the year						
cAdd lines 7a and 7b						
8Public Support (Subtract line 7c from line 6 )						

Section B. Total Support

Calendar year (or fiscal year beginning in)	(a) 2005	(b) 2006	(c) 2007	(d) 2008	(e) 2009	(f) Total
9Amounts from line 6						
10aGross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources						
bUnrelated business taxable income (less section 511 taxes) from businesses acquired after June 30, 1975						
cAdd lines 10a and 10b						
11Net income from unrelated business activities not included in line 10b, whether or not the business is regularly carried on						
12Other income. Do not include gain or loss from the sale of capital assets (Explain in Part IV.)						
13Total support (Add lines 9, 10c, 11 and 12.)						

14First Five Years If the Form 990 is for the organization's first, second, third, fourth, or fifth tax year as a 501(c)(3) organization, check this box and **stop here**

☐

Section C. Computation of Public Support Percentage

15Public Support Percentage for 2009 (line 8 column (f) divided by line 13 column (f))	15	
16Public support percentage from 2008 Schedule A, Part III, line 15	16	

Section D. Computation of Investment Income Percentage

17Investment income percentage for <b>2009</b> (line 10c column (f) divided by line 13 column (f))	17	
18Investment income percentage from <b>2008</b> Schedule A, Part III, line 17	18	

19a**33 1/3% support tests—2009.** If the organization did not check the box on line 14, and line 15 is more than 33 1/3% and line 17 is not more than 33 1/3%, check this box and **stop here.** The organization qualifies as a publicly supported organization

☐

b**33 1/3% support tests—2008.** If the organization did not check a box on line 14 or line 19a, and line 16 is more than 33 1/3% and line 18 is not more than 33 1/3%, check this box and **stop here.** The organization qualifies as a publicly supported organization

☐

20**Private Foundation** If the organization did not check a box on line 14, 19a or 19b, check this box and see instructions

☐



Part IV

**Supplemental Information.** Supplemental Information. Complete this part to provide the explanation required by Part II, line 10; Part II, line 17a or 17b; or Part III, line 12. Provide any other additional information. See instructions

Explanation
PART 1, LINE 4 - CHILDREN'S MERCY HOSPITAL IN KANSAS CITY, MISSOURI AND MASSACHUSETTS GENERAL HOSPITAL IN BOSTON, MASSACHUSETTS

Additional Data

Software ID:  
Software Version:  
EIN: 20-2993509  
Name: Stowers Institute for Medical Research

Form 990, Part IX - Statement of Functional Expenses - 24a - 24e Other Expenses

<i>Do not include amounts reported on line 6b, 8b, 9b, and 10b of Part VIII.</i>	(A) Total expenses	(B) Program service expenses	(C) Management and general expenses	(D) Fundraising expenses
COST-SHARING WITH RELATED ORG	16,809,457	15,128,511	1,680,946	
LAB SUPPLIES	6,386,139	5,747,525	638,614	
NON-CAPITAL EQUIPMENT	288,108	259,297	28,811	
SCIENTIFIC CONSULTING	233,059	209,753	23,306	
COLLABORATION EXPENSE	134,804	121,324	13,480	

SCHEDULE D  
(Form 990)

Supplemental Financial Statements

▶ Complete if the organization answered "Yes," to Form 990, Part IV, line 6, 7, 8, 9, 10, 11, or 12.  
▶ Attach to Form 990. ▶ See separate instructions.

OMB No 1545-0047

2009

Open to Public Inspection

Department of the Treasury  
Internal Revenue Service

Name of the organization Stowers Institute for Medical Research	Employer identification number 20-2993509
--	--

Part I Organizations Maintaining Donor Advised Funds or Other Similar Funds or Accounts. Complete if the organization answered "Yes" to Form 990, Part IV, line 6.

	(a) Donor advised funds	(b) Funds and other accounts
1	Total number at end of year	
2	Aggregate contributions to (during year)	
3	Aggregate grants from (during year)	
4	Aggregate value at end of year	
5	Did the organization inform all donors and donor advisors in writing that the assets held in donor advised funds are the organization's property, subject to the organization's exclusive legal control?	<input type="checkbox"/> Yes <input type="checkbox"/> No
6	Did the organization inform all grantees, donors, and donor advisors in writing that grant funds may be used only for charitable purposes and not for the benefit of the donor or donor advisor, or for any other purpose conferring impermissible private benefit	<input type="checkbox"/> Yes <input type="checkbox"/> No

Part II Conservation Easements. Complete if the organization answered "Yes" to Form 990, Part IV, line 7.

1	Purpose(s) of conservation easements held by the organization (check all that apply) <input type="checkbox"/> Preservation of land for public use (e g , recreation or pleasure) <input type="checkbox"/> Protection of natural habitat <input type="checkbox"/> Preservation of open space <input type="checkbox"/> Preservation of an historically importantly land area <input type="checkbox"/> Preservation of a certified historic structure
2	Complete lines 2a–2d if the organization held a qualified conservation contribution in the form of a conservation easement on the last day of the tax year
a	Total number of conservation easements
b	Total acreage restricted by conservation easements
c	Number of conservation easements on a certified historic structure included in (a)
d	Number of conservation easements included in (c) acquired after 8/17/06
3	Number of conservation easements modified, transferred, released, extinguished, or terminated by the organization during the taxable year ▶ _____
4	Number of states where property subject to conservation easement is located ▶ _____
5	Does the organization have a written policy regarding the periodic monitoring, inspection, handling of violations, and enforcement of the conservation easements it holds? <input type="checkbox"/> Yes <input type="checkbox"/> No
6	Staff and volunteer hours devoted to monitoring, inspecting and enforcing conservation easements during the year ▶ _____
7	Amount of expenses incurred in monitoring, inspecting, and enforcing conservation easements during the year ▶ \$ _____
8	Does each conservation easement reported on line 2(d) above satisfy the requirements of section 170(h)(4)(B)(i) and 170(h)(4)(B)(ii)? <input type="checkbox"/> Yes <input type="checkbox"/> No
9	In Part XIV, describe how the organization reports conservation easements in its revenue and expense statement, and balance sheet, and include, if applicable, the text of the footnote to the organization's financial statements that describes the organization's accounting for conservation easements

Part III Organizations Maintaining Collections of Art, Historical Treasures, or Other Similar Assets. Complete if the organization answered "Yes" to Form 990, Part IV, line 8.

1a	If the organization elected, as permitted under SFAS 116, not to report in its revenue statement and balance sheet works of art, historical treasures, or other similar assets held for public exhibition, education or research in furtherance of public service, provide, in Part XIV, the text of the footnote to its financial statements that describes these items
b	If the organization elected, as permitted under SFAS 116, to report in its revenue statement and balance sheet works of art, historical treasures, or other similar assets held for public exhibition, education, or research in furtherance of public service, provide the following amounts relating to these items
(i)	Revenues included in Form 990, Part VIII, line 1 ▶ \$ _____
(ii)	Assets included in Form 990, Part X ▶ \$ _____
2	If the organization received or held works of art, historical treasures, or other similar assets for financial gain, provide the following amounts required to be reported under SFAS 116 relating to these items
a	Revenues included in Form 990, Part VIII, line 1 ▶ \$ _____
b	Assets included in Form 990, Part X ▶ \$ _____

Part III

Organizations Maintaining Collections of Art, Historical Treasures, or Other Similar Assets (continued)

3

Using the organization's accession and other records, check any of the following that are a significant use of its collection items (check all that apply)

a

☐ Public exhibition

b

☐ Scholarly research

c

☐ Preservation for future generations

d

☐ Loan or exchange programs

e

☐ Other

4

Provide a description of the organization's collections and explain how they further the organization's exempt purpose in Part XIV

5

During the year, did the organization solicit or receive donations of art, historical treasures or other similar assets to be sold to raise funds rather than to be maintained as part of the organization's collection?

☐ Yes

☐ No

Part IV

Escrow and Custodial Arrangements. Complete if the organization answered "Yes" to Form 990, Part IV, line 9, or reported an amount on Form 990, Part X, line 21.

1a

Is the organization an agent, trustee, custodian or other intermediary for contributions or other assets not included on Form 990, Part X?

☐ Yes

☐ No

b

If "Yes," explain the arrangement in Part XIV and complete the following table

	Amount
1c	
1d	
1e	
1f	

c

Beginning balance

d

Additions during the year

e

Distributions during the year

f

Ending balance

2a

Did the organization include an amount on Form 990, Part X, line 21?

☐ Yes

☐ No

b

If "Yes," explain the arrangement in Part XIV

Part V

Endowment Funds. Complete if the organization answered "Yes" to Form 990, Part IV, line 10.

	(a)Current Year	(b)Prior Year	(c)Two Years Back	(d)Three Years Back	(e)Four Years Back
1a	Beginning of year balance . . . . .				
b	Contributions . . . . .				
c	Investment earnings or losses . . . . .				
d	Grants or scholarships . . . . .				
e	Other expenditures for facilities and programs . . . . .				
f	Administrative expenses . . . . .				
g	End of year balance . . . . .				

2

Provide the estimated percentage of the year end balance held as

a

Board designated or quasi-endowment ▶ %

b

Permanent endowment ▶ %

c

Term endowment ▶ %

3a

Are there endowment funds not in the possession of the organization that are held and administered for the organization by

(i)

unrelated organizations . . . . .

3a(i)

☐

☐

(ii)

related organizations . . . . .

3a(ii)

☐

☐

b

If "Yes" to 3a(ii), are the related organizations listed as required on Schedule R? . . . . .

3b

☐

☐

4

Describe in Part XIV the intended uses of the organization's endowment funds

Part VI

Investments—Land, Buildings, and Equipment. See Form 990, Part X, line 10.

Description of investment	(a) Cost or other basis (investment)	(b)Cost or other basis (other)	(c) Accumulated depreciation	(d) Book value
1a Land . . . . .	0	3,400,000		3,400,000
b Buildings . . . . .	0	223,542,438	52,734,917	170,807,521
c Leasehold improvements . . . . .	0	806,660	701,361	105,299
d Equipment . . . . .	0	81,968,842	54,160,086	27,808,756
e Other . . . . .	0	6,331	0	6,331
Total. Add lines 1a-1e (Column (d) should equal Form 990, Part X, column (B), line 10(c).) . . . . .				202,127,907



Part XI Reconciliation of Change in Net Assets from Form 990 to Financial Statements		
1	Total revenue (Form 990, Part VIII, column (A), line 12)	1
2	Total expenses (Form 990, Part IX, column (A), line 25)	2
3	Excess or (deficit) for the year Subtract line 2 from line 1	3
4	Net unrealized gains (losses) on investments	4
5	Donated services and use of facilities	5
6	Investment expenses	6
7	Prior period adjustments	7
8	Other (Describe in Part XIV)	8
9	Total adjustments (net) Add lines 4 - 8	9
10	Excess or (deficit) for the year per financial statements Combine lines 3 and 9	10

Part XII Reconciliation of Revenue per Audited Financial Statements With Revenue per Return		
1	Total revenue, gains, and other support per audited financial statements . . . . .	1
2	Amounts included on line 1 but not on Form 990, Part VIII, line 12	
a	Net unrealized gains on investments . . . . .2a	
b	Donated services and use of facilities . . . . .2b	
c	Recoveries of prior year grants . . . . .2c	
d	Other (Describe in Part XIV) . . . . .2d	
e	Add lines 2a through 2d . . . . .2e	
3	Subtract line 2e from line 1 . . . . .3	
4	Amounts included on Form 990, Part VIII, line 12, but not on line 1	
a	Investment expenses not included on Form 990, Part VIII, line 7b . . . . .4a	
b	Other (Describe in Part XIV) . . . . .4b	
c	Add lines 4a and 4b . . . . .4c	
5	Total Revenue Add lines 3 and 4c. (This should equal Form 990, Part I, line 12 ) . . . . .5	

Part XIII Reconciliation of Expenses per Audited Financial Statements With Expenses per Return		
1	Total expenses and losses per audited financial statements . . . . .	1
2	Amounts included on line 1 but not on Form 990, Part IX, line 25	
a	Donated services and use of facilities . . . . .2a	
b	Prior year adjustments . . . . .2b	
c	Other losses . . . . .2c	
d	Other (Describe in Part XIV) . . . . .2d	
e	Add lines 2a through 2d . . . . .2e	
3	Subtract line 2e from line 1 . . . . .3	
4	Amounts included on Form 990, Part IX, line 25, but not on line 1:	
a	Investment expenses not included on Form 990, Part VIII, line 7b . . . . .4a	
b	Other (Describe in Part XIV) . . . . .4b	
c	Add lines 4a and 4b . . . . .4c	
5	Total expenses Add lines 3 and 4c. (This should equal Form 990, Part I, line 18 ) . . . . .5	

Part XIV Supplemental Information

Complete this part to provide the descriptions required for Part II, lines 3, 5, and 9, Part III, lines 1a and 4, Part IV, lines 1b and 2b, Part V, line 4, Part X, Part XI, line 8, Part XII, lines 2d and 4b, and Part XIII, lines 2d and 4b. Also complete this part to provide any additional information.

Identifier	Return Reference	Explanation
SCHEDULE D		PART X, LINE 2 - SUMMARY OF FIN 48 CONSOLIDATED FOOTNOTE AS IT APPLIES TO STOWERS INSTITUTE FOR MEDICAL RESEARCH - AN INTERPRETATION OF FASB STATEMENT NO. 109. THIS INTERPRETATION CLARIFIES THE ACCOUNTING FOR UNCERTAINTY IN INCOME TAXES RECOGNIZED IN AN ENTERPRISE'S FINANCIAL STATEMENTS IN ACCORDANCE WITH FASB STATEMENT NO. 109, ACCOUNTING FOR INCOME TAXES. THIS INTERPRETATION ALSO PRESCRIBES A RECOGNITION THRESHOLD AND MEASUREMENT ATTRIBUTE FOR THE FINANCIAL STATEMENT RECOGNITION AND MEASUREMENT OF A TAX POSITION TAKEN OR EXPECTED TO BE TAKEN IN A TAX RETURN. STOWERS INSTITUTE FOR MEDICAL RESEARCH IS A TAX-EXEMPT ENTITY AS DESCRIBED IN SECTION 501 (c)(3) OF THE CODE. THEREFORE, IT IS STOWERS INSTITUTE FOR MEDICAL RESEARCH TAX POSITION THAT THEY ARE EXEMPT FROM FEDERAL INCOME TAXES. STOWERS INSTITUTE FOR MEDICAL RESEARCH ADOPTED FIN 48 EFFECTIVE JANUARY 1, 2007 WITH NO IMPACT TO ITS FINANCIAL STATEMENTS.

Schedule I  
(Form 990)

Department of the Treasury  
Internal Revenue Service

Grants and Other Assistance to Organizations,  
Governments and Individuals in the United States

Complete if the organization answered "Yes," to Form 990, Part IV, line 21 or 22.  
▶ Attach to Form 990

OMB No 1545-0047

2009

Open to Public  
Inspection

Name of the organization  
Stowers Institute for Medical Research

Employer identification number  
20-2993509

Part I

General Information on Grants and Assistance

- 1

Does the organization maintain records to substantiate the amount of the grants or assistance, the grantees' eligibility for the grants or assistance, and the selection criteria used to award the grants or assistance? . . . . .

Yes

No
- 2

Describe in Part IV the organization's procedures for monitoring the use of grant funds in the United States

Part II

Grants and Other Assistance to Governments and Organizations in the United States. Complete if the organization answered "Yes" to Form 990, Part IV, line 21 for any recipient that received more than \$5,000. Check this box if no one recipient received more than \$5,000. Use Part IV and Schedule I-1 (Form 990) if additional space is needed . . . . .

(a) Name and address of organization or government	(b) EIN	(c) IRC Code section if applicable	(d) Amount of cash grant	(e) Amount of non-cash assistance	(f) Method of valuation (book, FMV , appraisal, other)	(g) Description of non-cash assistance	(h) Purpose of grant or assistance
--	---------	------------------------------------	--------------------------	-----------------------------------	--	--	------------------------------------

2

Enter total number of section 501(c)(3) and government organizations . . . . .

3

Enter total number of other organizations . . . . .

**Part III** **Grants and Other Assistance to Individuals in the United States.** Complete if the organization answered "Yes" to Form 990, Part IV, line 22.  
Use Schedule I-1 (Form 990) if additional space is needed.

(a)Type of grant or assistance	(b)Number of recipients	(c)Amount of cash grant	(d)Amount of non-cash assistance	(e)Method of valuation (book, FMV , appraisal, other)	(f)Description of non-cash assistance
STIPENDS/FELLOWSHIPS	75	1,326,774		N/A	N/A
See Additional Data Table					

**Part IV** **Supplemental Information.** Complete this part to provide the information required in Part I, line 2, and any other additional information.

[illegible]



Schedule J  
(Form 990)

Department of the Treasury  
Internal Revenue Service

Compensation Information

For certain Officers, Directors, Trustees, Key Employees, and Highest Compensated Employees

▶ Complete if the organization answered "Yes" to Form 990, Part IV, question 23.

▶ Attach to Form 990. ▶ See separate instructions.

OMB No 1545-0047

2009

Open to Public Inspection

Name of the organization  
Stowers Institute for Medical Research

Employer identification number  
20-2993509

Part I

Questions Regarding Compensation

		Yes	No
1a	Check the appropriate box(es) if the organization provided any of the following to or for a person listed in Form 990, Part VII, Section A, line 1a. Complete Part III to provide any relevant information regarding these items. <div><div><input type="checkbox"/> First-class or charter travel</div><div><input type="checkbox"/> Travel for companions</div><div><input checked="" type="checkbox"/> Tax idemnification and gross-up payments</div><div><input type="checkbox"/> Discretionary spending account</div><div><input type="checkbox"/> Housing allowance or residence for personal use</div><div><input type="checkbox"/> Payments for business use of personal residence</div><div><input checked="" type="checkbox"/> Health or social club dues or initiation fees</div><div><input type="checkbox"/> Personal services (e g , maid, chauffeur, chef)</div></div>		
b	If any of the boxes in line 1a are checked, did the organization follow a written policy regarding payment or reimbursement or provision of all the expenses described above? If "No," complete Part III to explain	1b	Yes
2	Did the organization require substantiation prior to reimbursing or allowing expenses incurred by all officers, directors, trustees, and the CEO/Executive Director, regarding the items checked in line 1a?	2	Yes
3	Indicate which, if any, of the following the organization uses to establish the compensation of the organization's CEO/Executive Director. Check all that apply. <div><div><input checked="" type="checkbox"/> Compensation committee</div><div><input checked="" type="checkbox"/> Independent compensation consultant</div><div><input type="checkbox"/> Form 990 of other organizations</div><div><input checked="" type="checkbox"/> Written employment contract</div><div><input checked="" type="checkbox"/> Compensation survey or study</div><div><input checked="" type="checkbox"/> Approval by the board or compensation committee</div></div>		
4	During the year, did any person listed in Form 990, Part VII, Section A, line 1a with respect to the filing organization or a related organization: <div><div>a Receive a severance payment or change-of-control payment?</div><div>b Participate in, or receive payment from, a supplemental nonqualified retirement plan?</div><div>c Participate in, or receive payment from, an equity-based compensation arrangement?</div></div> If "Yes" to any of lines 4a-c, list the persons and provide the applicable amounts for each item in Part III	4a	No
		4b	No
		4c	No
5	Only 501(c)(3) and 501(c)(4) organizations only must complete lines 5-9. For persons listed in form 990, Part VII, Section A, line 1a, did the organization pay or accrue any compensation contingent on the revenues of: <div><div>a The organization?</div><div>b Any related organization?</div></div> If "Yes," to line 5a or 5b, describe in Part III	5a	No
		5b	No
6	For persons listed in form 990, Part VII, Section A, line 1a, did the organization pay or accrue any compensation contingent on the net earnings of: <div><div>a The organization?</div><div>b Any related organization?</div></div> If "Yes," to line 6a or 6b, describe in Part III	6a	No
		6b	No
7	For persons listed in Form 990, Part VII, Section A, line 1a, did the organization provide any non-fixed payments not described in lines 5 and 6? If "Yes," describe in Part III	7	No
8	Were any amounts reported in Form 990, Part VII, paid or accrued pursuant to a contract that was subject to the initial contract exception described in Regs section 53.4958-4(a)(3)? If "Yes," describe in Part III	8	No
9	If "Yes" to line 8, did the organization also follow the rebuttable presumption procedure described in Regulations section 53.4958-6(c)?	9	

**Part II** **Officers, Directors, Trustees, Key Employees, and Highest Compensated Employees.** Use Schedule J-1 if additional space needed.

For each individual whose compensation must be reported in Schedule J, report compensation from the organization on row (i) and from related organizations, described in the instructions on row (ii) Do not list any individuals that are not listed on Form 990, Part VII

**Note.** The sum of columns (B)(i)-(iii) must equal the applicable column (D) or column (E) amounts on Form 990, Part VII, line 1a

(A) Name		(B) Breakdown of W-2 and/or 1099-MISC compensation			(C) Retirement and other deferred compensation	(D) Nontaxable benefits	(E) Total of columns (B)(i)-(D)	(F) Compensation reported in prior Form 990 or Form 990-EZ
		(i) Base compensation	(ii) Bonus & incentive compensation	(iii) Other reportable compensation				
RICHARD WBROWN	(i)	0	0	0	0	0	0	0
	(ii)	1,556,066		24,688	36,750	10,452	1,627,956	
DAVID AWELTE	(i)	0	0	0	0	0	0	0
	(ii)	828,407		13,449	36,750	14,585	893,191	
RODERICK L STURGEON	(i)	0	0	0	0	0	0	0
	(ii)	1,019,869		33,378	36,750	14,052	1,104,049	
WILLIAM B NEAVES	(i)	1,087,139		23,755	36,750	11,219	1,158,863	
	(ii)	0	0	0	0	0	0	0
DAVID M CHAO	(i)	399,088		975	36,750	651	437,464	
	(ii)	226,667	0	292	0	792	227,751	0
ROBERT E KRUMLAUF	(i)	427,959		2,791	36,750	13,379	480,879	
	(ii)	0	0	0	0	0	0	0
RONALD C CONAWAY	(i)	235,267		1,151	35,290	1,394	273,102	
	(ii)	0	0	0	0	0	0	0
JOAN W CONAWAY	(i)	235,266		580	35,290	10,211	281,347	
	(ii)	0	0	0	0	0	0	0
JERRY L WORKMAN	(i)	230,875		685	34,631	6,508	272,699	
	(ii)	0	0	0	0	0	0	0
R SCOTT HAWLEY	(i)	223,845		2,101	34,490	18,631	279,067	
	(ii)	0	0	0	0	0	0	0
ARCADY R MUSHEGIAN	(i)	208,888		664	31,633	14,484	255,669	
	(ii)	0	0	0	0	0	0	0

Part III

Supplemental Information

Complete this part to provide the information, explanation, or descriptions required for Part I, lines 1a, 1b, 4c, 5a, 5b, 6a, 6b, 7, and 8. Also complete this part for any additional information.

Identifier	Return Reference	Explanation
Schedule J		PART I, LINE 1A - SIMR HAS WRITTEN EMPLOYMENT CONTRACTS WITH WILLIAM B. NEAVES, CEO, AND DAVID M. CHAO, PRESIDENT, WHICH PROVIDES FOR TAXABLE TERM LIFE BENEFITS AND FOR THE EXECUTIVES TO RECEIVE TAX GROSS-UP PAYMENTS SUFFICIENT TO COVER THE TAXES ON THE BENEFITS. PART 1, LINE 1B SIMR PROVIDED THE BENEFITS DESCRIBED IN RESPONSE TO LINE 1A PURSUANT TO WRITTEN EMPLOYMENT CONTRACTS THAT WERE APPROVED BY SIMR'S GOVERNING BOARD, SEE RESPONSE TO FORM 990, PART VI, SECTION B, LINE 15, FOR ADDITIONAL PROCESSES RELATED TO DETERMINING EXECUTIVE COMPENSATION.

Schedule L  
(Form 990 or 990-EZ)

Department of the Treasury  
Internal Revenue Service

Transactions with Interested Persons

▶ Complete if the organization answered "Yes" on Form 990, Part IV, lines 25a, 25b, 26, 27, 28a, 28b, or 28c, or Form 990-EZ, Part V lines 38a or 40b.  
▶ Attach to Form 990 or Form 990-EZ. ▶ See separate instructions.

OMB No 1545-0047

2009

Open to Public Inspection

Name of the organization  
Stowers Institute for Medical Research

Employer identification number  
20-2993509

Part I

Excess Benefit Transactions (section 501(c)(3) and section 501 (c)(4) organizations only).  
Complete if the organization answered "Yes" on Form 990, Part IV, line 25a or 25b, or Form 990-EZ, Part V, line 40b

1	(a) Name of disqualified person	(b) Description of transaction	(c) Corrected? Yes No
2	Enter the amount of tax imposed on the organization managers or disqualified persons during the year under section 4958 . . . . . ▶ \$		
3	Enter the amount of tax, if any, on line 2, above, reimbursed by the organization . . . . . ▶ \$		

Part II

Loans to and/or From Interested Persons.  
Complete if the organization answered "Yes" on Form 990, Part IV, line 26, or Form 990-EZ, Part V, line 38a

(a) Name of interested person and purpose	(b) Loan to or from the organization?  To From	(c) Original principal amount	(d) Balance due	(e) In default?		(f) Approved by board or committee?		(g) Written agreement?	
				Yes	No	Yes	No	Yes	No
Total . . . . . ▶ \$									

Part III

Grants or Assistance Benefitting Interested Persons.  
Complete if the organization answered "Yes" on Form 990, Part IV, line 27.

(a) Name of interested person	(b) Relationship between interested person and the organization	(c) Amount of grant or type of assistance
-------------------------------	---	---

Part IV

Business Transactions Involving Interested Persons.  
Complete if the organization answered "Yes" on Form 990, Part IV, line 28a, 28b, or 28c.

(a) Name of interested person	(b) Relationship between interested person and the organization	(c) Amount of transaction	(d) Description of transaction	(e) Sharing of organization's revenues? Yes No
AMERICAN CENTURY COMPANIES INC	SEE SCHEDULE O		SEE SCH O	No

SCHEDULE M  
(Form 990)

Department of the Treasury  
Internal Revenue Service

NonCash Contributions

►Complete if the organization answered "Yes" on Form 990, Part IV, lines 29 or 30.  
► Attach to Form 990.

OMB No 1545-0047

2009

Open to Public Inspection

Name of the organization  
Stowers Institute for Medical Research

Employer identification number  
20-2993509

Part I Types of Property

	(a) Check if applicable	(b) Number of Contributions	(c) Revenues reported on Form 990, Part VIII, line 1g	(d) Method of determining revenues
1 Art—Works of art . . . . .				
2 Art—Historical treasures . . . . .				
3 Art—Fractional interests . . . . .				
4 Books and publications . . . . .				
5 Clothing and household goods . . . . .				
6 Cars and other vehicles . . . . .				
7 Boats and planes . . . . .				
8 Intellectual property . . . . .				
9 Securities—Publicly traded . . . . .	X	3	263,801	FAIR MARKET VALUE
10 Securities—Closely held stock . . . . .				
11 Securities—Partnership, LLC, or trust interests . . . . .				
12 Securities—Miscellaneous . . . . .				
13 Qualified conservation contribution—Historic structures . . . . .				
14 Qualified conservation contribution—Other . . . . .				
15 Real estate—Residential . . . . .				
16 Real estate—Commercial . . . . .				
17 Real estate—Other . . . . .				
18 Collectibles . . . . .				
19 Food inventory . . . . .				
20 Drugs and medical supplies . . . . .				
21 Taxidermy . . . . .				
22 Historical artifacts . . . . .				
23 Scientific specimens . . . . .				
24 Archeological artifacts . . . . .				
LAB				
25 Other ► ( <u>EQUIPMENT</u> ) . . . . .	X	1	8,505	FAIR MARKET VALUE
26 Other ► ( <u>                    </u> ) . . . . .				
27 Other ► ( <u>                    </u> ) . . . . .				
28 Other ► ( <u>                    </u> ) . . . . .				

29

Number of Forms 8283 received by the organization during the tax year for contributions for which the organization completed Form 8283, Part IV, Donee Acknowledgement . . . . .

30a

During the year, did the organization receive by contribution any property reported in Part I, lines 1-28 that it must hold for at least three years from the date of the initial contribution, and which is not required to be used for exempt purposes for the entire holding period? . . . . .

31

Does the organization have a gift acceptance policy that requires the review of any non-standard contributions?

32a

Does the organization hire or use third parties or related organizations to solicit, process, or sell non-cash contributions? . . . . .

33

If the organization did not report revenues in column (c) for a type of property for which column (a) is checked, describe in Part II

Yes

No

For Privacy Act and Paperwork Reduction Act Notice, see the Instructions for Form 990.

Cat No 51227J

Schedule M (Form 990) 2009

Part II

**Supplemental Information.** Complete this part to provide the information required by Part I, lines 30b, 32b, and 33. Also complete this part for any additional information.

Identifier	Return Reference	Explanation
------------	------------------	-------------

SCHEDULE O  
(Form 990)

Department of the Treasury  
Internal Revenue Service

Supplemental Information to Form 990

OMB No 1545-0047

2009

Open to Public Inspection

Name of the organization  
Stowers Institute for Medical Research

Employer identification number  
20-2993509

Identifier	Return Reference	Explanation
SUPPLEMENTAL INFORMATION		FORM 990, PART III, LINE 1 - THE STOWERS INSTITUTE FOR MEDICAL RESEARCH PERFORMS MEDICAL RESEARCH IN THE PUBLIC INTEREST IN CONJUNCTION WITH CHILDREN'S MERCY HOSPITAL IN KANSAS CITY, MISSOURI AND MASSACHUSETTS GENERAL HOSPITAL IN BOSTON, MASSACHUSETTS - BOTH SECTION 501 (C)(3) AND 170(B)(1)(A)(III) HOSPITALS, WITH THE GOAL OF EXPANDING OUR UNDERSTANDING OF FUNDAMENTAL PROCESSES IN LIVING CELLS AND IMPROVING LIFE'S QUALITY THROUGH INNOVATIVE APPROACHES TO THE CAUSES, TREATMENT, AND PREVENTION OF DISEASE FORM 990, PART III, LINE 4 - SIMR'S ACCOMPLISHMENTS ARE DESCRIBED AT END OF SCHEDULE O FORM 990, PART VI, LINE 2 - JAMES E STOWERS JR, RICHARD W BROWN, AND DAVID A WELTE, DIRECTORS OF SIMR, HAVE A BUSINESS RELATIONSHIP, THEY ALL SERVE ON THE BOARD OF AMERICAN CENTURY COMPANIES, INC AS DESCRIBED IN RESPONSE TO SCHEDULE L, PART IV JAMES E STOWERS JR, RICHARD W BROWN, WILLIAM B NEAVES, DAVID M CHAO, AND RODERICK L STURGEON, DIRECTORS OF SIMR, HAVE A BUSINESS RELATIONSHIP, THEY ALL SERVE ON THE BOARD OF BIOMED VALLEY DISCOVERIES, INC, A RELATED PARTY AS DISCUSSED ON SCHEDULE R FORM 990, PART VI, LINE 11A - THE DATA AND INFORMATION NECESSARY TO PREPARE SIMR'S FORM 990 WAS COMPILED BY SIMR'S ACCOUNTING DEPARTMENT AND THEN REVIEWED BY OUR TAX ATTORNEY AT BRYAN CAVE, LLC KPMG, OUR EXTERNAL TAX PREPARERS, USE THIS INFORMATION TO PREPARE THE FORM 990 THE COMPLETED FORM 990, INCLUDING REQUIRED SCHEDULES, IS DISTRIBUTED IN ADVANCE TO ALL SIX OFFICERS OF SIMR FOR THEIR REVIEW AND COMMENTS BEFORE THE FORM 990 IS FILED WITH THE IRS AFTER THE PREPARATION AND REVIEW PROCESS DESCRIBED ABOVE, THE FORM 990, INCLUDING REQUIRED SCHEDULES, IS PROVIDED TO EACH VOTING MEMBER OF THE ORGANIZATION'S BOARD BEFORE IT IS FILED WITH THE IRS FORM 990, PART VI, LINE 12C - SIMR HAS ADOPTED A "CONFLICTS OF INTEREST AND DIRECTOR INDEPENDENCE POLICY" EACH DIRECTOR, OFFICER, AND OTHER PERSON WHO IS IN A POSITION TO EXERCISE SUBSTANTIAL INFLUENCE OVER DECISIONS OF SIMR ARE REQUIRED TO ANNUALLY COMPLETE AND SIGN A DISCLOSURE STATEMENT THAT IS PART OF THE POLICY A COVERED PERSON MUST ALSO DISCLOSE THE EXISTENCE OF A POTENTIAL CONFLICT AND ALL MATERIAL FACTS TO THE GOVERNING BOARD AS SOON AS THE PERSON HAS KNOWLEDGE THAT A POTENTIAL CONFLICT MIGHT EXIST SIMR CONDUCTS PERIODIC AND ADHOC REVIEWS OF TRANSACTIONS AND AGREEMENTS TO INSURE THAT IT ENGAGES ONLY IN ACTIVITIES THAT ARE CONSISTENT WITH ITS TAX-EXEMPT PURPOSE FORM 990, PART VI, LINES 15A & 15B - THE PROCESS FOR DETERMINING COMPENSATION OF SIMR'S PRESIDENT AND CEO INCLUDED RETAINING THE SERVICES OF A NATIONALLY KNOWN COMPENSATION CONSULTANT TO PROVIDE DATA AND ANALYSIS TO DETERMINE COMPARABLE SALARY AND BENEFITS FOR SIMILARLY QUALIFIED PERSONS IN COMPARABLE POSTIONS AT SIMILARLY SITUATED ORGANIZATIONS COMPENSATION WAS DOCUMENTED IN EMPLOYMENT CONTRACTS WHICH WERE APPROVED BY THE GOVERNING BODY AS DOCUMENTED IN THE OFFICIAL MINUTES THE PROCESS WAS LAST UNDERTAKEN FOR THE PRESIDENT AND CEO POSITIONS IN 2009 AT THE TIME THE CURRENT CONTRACTS IN EFFECT WERE EXECUTED FORM 990, PART VI, LINE 19 - SIMR'S GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS ARE AVAILABLE ON REQUEST FORM 990, PART VII - RICHARD W BROWN, RODERICK L STURGEON, AND DAVID A WELTE ARE COMPENSATED IN THEIR ROLE AS OFFICERS OF STOWERS RESOURCE MANAGEMENT, A SUPPORTING ORGANIZATION OF SIMR AS REPORTED IN SCHEDULE R DAVID M CHAO WAS COMPENSATED FOR HIS ROLE AS OFFICER OF A RELATED PARTY, BIOMED VALLEY DISCOVERIES, INC ("BVD") FOR THE SIX MONTHS ENDING JUNE 30, 2009, EFFECTIVE JULY 1, 2009, CHAO BECAME PRESIDENT OF SIMR AS REPORTED, HIS COMPENSATION FROM SIMR FOR THE SIX MONTHS ENDING DECEMBER 31, 2009 WAS \$400,063, HIS SIMR COMPENSATION FOR A FULL TWELVE MONTHS WOULD HAVE BEEN \$800,126
SUPPLEMENTAL INFORMATION		SCHEDULE L, PART IV - CURRENT DIRECTORS AND OFFICERS OF SIMR, RICHARD W BROWN, DAVID A WELTE, AND JAMES E STOWERS JR ARE DIRECTORS OF AMERICAN CENTURY COMPANIES, INC ("ACCI") JAMES E STOWERS JR IS THE FOUNDER OF ACCI AND ALONG WITH OTHER FAMILY MEMBERS RETAINS A CONTROLLING VOTING INTEREST IN ACCI SIMR RECEIVES INVESTMENT MANAGEMENT SERVICES FROM AMERICAN CENTURY INVESTMENTS ("ACI") SIMR PAYS THE SAME ADMINISTRATIVE FEES FOR THESE SERVICES AS ANY ARMS-LENGTH MUTUAL FUND INVESTOR THE VALUE OF THESE SERVICES, ESTIMATED BY MULTIPLYING SIMR'S AVERAGE AMOUNT OF MUTAL FUND HOLDINGS THROUGHOUT THE YEAR BY THE PUBLISHED ADMINISTRATIVE FEE PERCENTAGE FOR THE APPLICABLE FUNDS, WAS APPROXIMATELY \$862,000 IN SELECTING ACI TO MANAGE ITS LIQUID INVESTMENTS, SIMR SELECTED A HIGH QUALITY MUTUAL FUND COMPANY WITH AN OUTSTANDING TRACK RECORD SCHEDULE R, PART V, LINE 2 1) IN 2009, SIMR ENTERED INTO A LEASE WITH STOWERS REAL ESTATE HOLDING CORP ("SREHC") A 501(C)(2) RELATED PARTY AS DESCRIBED BELOW IN (3) FOR USE OF A CERTAIN BUILDING AND PROPERTY, SIMR SUBLEASED ABOUT 6% OF THIS TOTAL PROPERTY TO BIOMED VALLEY DISCOVERIES, INC ("BVD") AS REFLECTED ON FORM 990, PART VIII, BVD MARKET VALUE LEASE PAYMENTS TO SIMR IN 2009 TOTALED \$415,575 AND SIMR HAD OFFSETTING AMOUNT OF EXPENSES DUE TO SIMR RENT PAID TO SREHC BVD IS A CONTROLLED PARTY OF BIOMED VALLEY CORPORATION ("BVC"), BVC AND BVD ARE RELATED PARTIES OF SIMR AS REPORTED ON SCHEDULE R THE RENT PAYMENTS FROM BVD DID NOT REDUCE BVD'S "NET UNRELATED INCOME" WITHIN THE MEANING OF CODE SECTION 512(b)(13)(A) THEREFORE, NO PORTION OF THE RENT PAYMENTS FROM BVD CONSTITUTE UNRELATED BUSINESS INCOME TO SIMR UNDER CODE SECTION 512(b)(13) 2) DURING 2009, BIOMED VALLEY DISCOVERIES, INC ("BVD") TEMPORARILY USED OFFICE SPACE ON SIMR CAMPUS TOTALING LESS THAN 500 SQUARE FEET OF THE MORE THAN 600,000 SQUARE FEET CAMPUS BVD PAYMENTS TO SIMR IN 2009 TOTALED \$10,636 BVD IS NOW LOCATED ON A SEPARATE CAMPUS AS REPORTED IN (1) ABOVE 3) IN MARCH 2009, SIMR ENTERED INTO A LEASE FOR A 280,000 SQUARE FEET BUILDING WITH STOWERS REAL ESTATE HOLDING CORPORATION ("SREHC"), A 501 (C)(2) TAX EXEMPT ORGANIZATION THAT IS A RELATED PARTY OF SIMR SIMR LEASE PAYMENTS TO SREHC IN 2009 TOTALED \$2,230,551 4) SIMR RECEIVED REIMBURESMENT FROM STOWERS REAL ESTATE HOLDING CORP ("SREHC"), A 501(C)(2) TAX EXEMPT ORGANIZATION THAT IS A RELATED PARTY OF SIMR, IN THE AMOUNT OF \$148,511 FOR CERTAIN SERVICES AND EXPENSES INCURRED ON SREHC'S BEHALF 5) ALL OTHER TRANSACTIONS FOR 1(c), (f), (m), (n), and (o) WERE BETWEEN RELATED 501(C)(3) PUBLIC CHARITIES OR BELOW REPORTING THRESHOLDS

Identifier	Return Reference	Explanation
FORM 990, PART III, LINE 4		2009 Program Service Accomplishments The Stowers Institute for Medical Research ("SIMR") is a private, nonprofit medical research organization with locations in Kansas City, Missouri and Cambridge, Massachusetts SIMR was founded in 1994 by Jim and Virginia Stowers, two cancer survivors who have dedicated their fortune to supporting basic research in cell and molecular biology that will provide long-term solutions to gene-based diseases SIMR conducts basic biomedical research in the public interest that will ultimately provide a greater understanding of the genes and proteins that control how cells in our bodies multiply, form tissues, and die Like a growing number of scientists today, Institute scientists are convinced that by studying the basic biology of cells they will discover how genes cause many diseases, including cancer, diabetes, and dementia Basic research conducted at SIMR should point the way to the development of new preventions, treatments, and cures for genetic diseases 2009 Notable Research Results In 2009, SIMR research teams made discoveries meriting publication in leading peer-reviewed scientific journals - 57 papers in all SIMR research teams also published 35 reviews, commentaries, chapters, and one book Highlights among 2009's published papers include " Linheng Li's Lab, in collaboration with the Cytometry, Histology, and Imaging Facilities, determined that inner bone surface stimulates blood stem cell proliferation in response to bone marrow damage by radiation (January 1 issue of Nature) " The Blanchette Lab elucidated how cellular machinery cuts and pastes protein-encoding RNAs in different ways to generate protein variants (February issue of Molecular Cell) " The Mak Lab elucidated how worm pheromones are made (February 10 issue of Proceedings of the National Academy of Sciences) " The Bioinformatics Center discovered that co-transmission of genes from one species to another during evolution predict that they belong to the same biochemical pathway (published online by PLoS One on April 24) " The Washburn Lab and Proteomics Center discovered that the protein Rtr1 modifies and regulates RNA polymerase II, which transcribes DNA into RNA (April 24 issue of Molecular Cell) " The Hawley Lab and Molecular Biology Facility identified a mutated gene by sequencing the entire genome of a mutant and pioneered a new way to use whole genome sequencing to determine gene function (May issue of Genetics) " The Gibson Lab found that different organisms use different patterns of cell division to make and maintain the linings of their organs and outer surface (published online by PLOS Computational Biology on June 12) " The Abmayr Lab reported on fruit fly proteins that function similarly to the human proteins Nephrin and Nephrin, which detoxify blood Their work sheds light on congenital nephrotic syndrome in which infants develop protein in urine and swelling of the body (July issue of Development) " The Trainor Lab demonstrated that a protein that regulates cell growth and proliferation also regulates spinal cord formation (July issue of Development) " The Xie Lab found that a regulator of protein synthesis keeps stem cells in a high potential state, which makes them capable of differentiating into many cell types (July 14 issue of Proceedings of National Academy of Sciences) " The Conaway Lab and Proteomics Center collaborated to show that the protein Alc1, a likely contributor to hepatocellular carcinoma, plays a role in packaging the approximately 2 meters of DNA in the human genome into a cell's nucleus (published online by Proceedings of the National Academy of Sciences on August 6) " The Shilatfard Lab and Jaspersen Lab identified an important step in the modification of DNA packaging which results in gene expression (August 10 issue of The Journal of Cell Biology) " Rong Li's Lab found that how sperm DNA is packaged determines how an egg rearranges structurally after the sperm fertilizes the egg (published online by PLoS One on September 29) " The Eggan Lab demonstrated that a small molecule inhibitor of TGF-β signaling can replace sox2 in reprogramming fibroblasts (October 8 issue of Cell Stem Cell) " The Kulesa Lab and Imaging Center pioneered a new way to watch organ development using fluorescently labeled cells and microscopy techniques (October/November/December issue of Organogenesis) " The Shilatfard Lab and Krumlauf Lab reported that the mixed lineage leukemia gene modifies DNA packaging and may regulate the expression of genes necessary for embryonic development (November issue of Molecular and Cellular Biology) " The Baumann Lab identified a human protein which prevents the end-to-end fusion of chromosomes which encode genetic information The protein prevents catastrophic defects in cell proliferation which may underlie the creation of cancer (November 4 issue of EMBO Journal) " The Gerton Lab collaborated with the Microarray Group to shed light on molecular mechanisms underlying human diseases which cause face and limb abnormalities in infants (published online by The Journal of Cell Biology on November 9) " The Workman Lab collaborated with the Bioinformatics and Proteomics Centers to identify a new complex that regulates gene expression (December 15 issue of Genes and Development) Comprehensive List of 2009 Original Research Papers, Reviews, Commentaries or Chapters, and Book Original Research Papers " Anderson JA, Gilliland WD, Langley CH Molecular population genetics and evolution of Drosophila meiosis genes Genetics 2009,181 177-185 " Asai-Coakwell M, French CR, Ye M, Garcha K, Bigot K, Perera AG, Staehling-Hampton K, Mema SC, Chanda B, Mushegian A, Bamforth S, Doschak MR, Li G, Dobbs MB, Giampietro PF, Brooks BP, Vijayalakshmi P, Sauve Y, Abitbol M, Sundaresan P, van Heyningen V, Pourque O, Underhill TM, Waskiewicz AJ, Lehmann OJ Incomplete penetrance and phenotypic variability characterize Gdf6-attributable oculo-skeletal phenotypes Hum Mol Genet 2009,18 1110-1121 " Aygun O, Xu X, Liu Y, Takahashi H, Kong SE, Conaway RC, Conaway JW, Svestrup JQ Direct inhibition of RNA polymerase II transcription by RECQL5 J Biol Chem 2009,284 23197-23203 " Blanchette M, Green RE, Macarthur S, Brooks AN, Brenner SE, Eisen MB, Rio DC Genome-wide analysis of alternative pre-mRNA splicing and RNA-binding specificities of the Drosophila hnRNP A/B family members Mol Cell 2009,33 438-449 " Blumenstiel JP, Noll AC, Griffiths JA, Perera AG, Walton KN, Gilliland WD, Hawley RS, Staehling-Hampton K Identification of EMS-induced mutations in Drosophila melanogaster by whole-genome sequencing Genetics 2009,182 25-32 " Butcher RA, Ragains JR, Li W, Ruvkun G, Clardy J, Mak HY Biosynthesis of the Caenorhabditis elegans dauer pheromone Proc Natl Acad Sci U S A 2009,106 1875-1879 " Camahort R, Shivaraju M, Mattingly M, Li B, Nakanishi S, Zhu D, Shilatfard A, Workman JL, Gerton JL Cse4 is part of an octameric nucleosome in budding yeast Mol Cell 2009,35 794-805 " Chen AE, Egli D, Niakan K, Deng J, Akutsu H, Yamaki M, Cowan C, Fitz-Gerald C, Zhang K, Melton DA, Eggan K Optimal timing of inner cell mass isolation increases the efficiency of human embryonic stem cell derivation and allows generation of sibling cell lines Cell Stem Cell 2009,4 103-106 " Cochran JC, Sindelar CV, Mulko NK, Collins KA, Kong SE, Hawley RS, Kull FJ ATPase cycle of the nonmotile kinesin NOD allows microtubule end tracking and drives chromosome movement Cell 2009,136 110-122 " Dang W, Steffen KK, Perry R, Dorsey JA, Johnson FB, Shilatfard A, Kaerberlein M, Kennedy BK, Berger SL Histone H4 lysine 16 acetylation regulates cellular lifespan Nature 2009,459 802-807 " Deng M, Gao J, Suraneni P, Li R Kinetochore-independent chromosome poleward movement during anaphase of meiosis II in mouse eggs PLoS ONE 2009,4 e5249 " Deng M, Li R Sperm chromatin-induced ectopic polar body extrusion in mouse eggs after ICSI and delayed egg activation PLoS One 2009,4 e7171

Identifier	Return Reference	Explanation
FORM 990,PART III,LINE 4		<p>" Ding N, Tomomori-Sato C, Sato S, Conaw ay RC, Conaw ay JW, Boyer TG MED19 and MED26 are synergistic functional targets of the RE1 silencing transcription factor in epigenetic silencing of neuronal gene expression J Biol Chem 2009,284 2648-2656 "</p> <p>" Dinglasan RR, Devenport M, Florens L, Johnson JR, McHugh CA, Donnelly-Doman M, Carucci DJ, Yates JR, 3rd, Jacobs-Lorena M The Anopheles gambiae adult midgut peritrophic matrix proteome Insect Biochem Mol Biol 2009,39 125-134 "</p> <p>" Egli D, Sandler VM, Shinohara ML, Cantor H, Eggan K Reprogramming after chromosome transfer into mouse blastomeres Curr Biol 2009,19 1403-1409 "</p> <p>" Ferreira ME, Prochasson P, Berndt KD, Workman JL, Wright AP Activator-binding domains of the SWI/SNF chromatin remodeling complex characterized in vitro are required for its recruitment to promoters in vivo FEBS J 2009,276 2557-2565 "</p> <p>" Gard S, Light W, Xiong B, Bose T, McNairn AJ, Harris B, Fleharty B, Seidel C, Brickner J, Gerton JL Cohesinopathy mutations disrupt the subnuclear organization of chromatin J Cell Biol 2009,187 455-462 "</p> <p>" Gibb S, Zagorska A, Melton K, Tenin G, Vacca I, Trainor P, Maroto M, Dale JK Interfering with Wnt signalling alters the periodicity of the segmentation clock Dev Biol 2009,330 21-31 "</p> <p>" Gilliland WD, Hughes SF, Vietti DR, Haw ley RS Congression of achiasmate chromosomes to the metaphase plate in Drosophila melanogaster oocytes Dev Biol 2009,325 122-128 "</p> <p>" Gilliland WD, Vietti DL, Schweppe NM, Guo F, Johnson TJ, Haw ley RS Hypoxia transiently sequesters Msp1 and Polo to collagenase-sensitive filaments in Drosophila prometaphase oocytes PLoS One 2009,4 e7544 "</p> <p>" Gottschalk AJ, Timmszky G, Kong SE, Jin J, Cai Y, Swanson SK, Washburn MP, Florens L, Ladurner AG, Conaw ay JW, Conaw ay RC Poly(ADP-ribosyl)ation directs recruitment and activation of an ATP-dependent chromatin remodeler Proc Natl Acad Sci U S A 2009,106 13770-13774 "</p> <p>" Harreman M, Taschner M, Sigurdsson S, Anindya R, Reid J, Somesh B, Kong SE, Banks CA, Conaw ay RC, Conaw ay JW, Svejstrup JQ Distinct ubiquitin ligases act sequentially for RNA polymerase II polyubiquitylation Proc Natl Acad Sci U S A 2009,106 20705-20710 "</p> <p>" Hartmann B, Castelo R, Blanchette M, Boue S, Rio DC, Valcarcel J Global analysis of alternative splicing regulation by insulin and wingless signaling in Drosophila cells Genome Biol 2009,10 R11 "</p> <p>" Hughes SE, Gilliland WD, Cotitta JL, Takeo S, Collins KA, Haw ley RS Heterochromatic threads connect oscillating chromosomes during prometaphase I in Drosophila oocytes PLoS Genet 2009,5 e1000348 "</p> <p>" Ichida JK, Blanchard J, Lam K, Son EY, Chung JE, Egli D, Loh KM, Carter AC, Di Giorgio FP, Koszka K, Huangfu D, Akutsu H, Liu DR, Rubin LL, Eggan K A small-molecule inhibitor of tgfbeta signaling replaces Sox2 in reprogramming by inducing Nanog Cell Stem Cell 2009,5 491-503 "</p> <p>" Iulianella A, Sharma M, Vanden Heuvel GB, Trainor PA Cux2 functions downstream of Notch signaling to regulate dorsal interneuron formation in the spinal cord Development 2009,136 2329-2334 "</p> <p>" Kim J, Guermah M, McGinty RK, Lee JS, Tang Z, Milne TA, Shilatifard A, Muir TW, Roeder RG RAD6-Mediated transcription-coupled H2B ubiquitylation directly stimulates H3K4 methylation in human cells Cell 2009,137 459-471 "</p> <p>" Kulesa PM, Stark DA, Steen J, Lansford R, Kasemeier-Kulesa JC Watching the assembly of an organ a single cell at a time using confocal multi-position photoactivation and multi-time acquisition Organogenesis 2009,5 238-247 "</p> <p>" Lee KK, Swanson SK, Florens L, Washburn MP, Workman JL Yeast Sgf73/Ataxin-7 serves to anchor the deubiquitination module into both SAGA and SIK(SALSA) HAT complexes Epigenetics &amp; chromatin 2009,2 2 "</p> <p>" Li B, Jackson J, Simon MD, Fleharty B, Gogol M, Seidel C, Workman JL, Shilatifard A Histone H3 lysine 36 dimethylation (H3K36me2) is sufficient to recruit the Rpd3s histone deacetylase complex and to repress spurious transcription J Biol Chem 2009,284 7970-7976 "</p> <p>" Li H, Kristensen DM, Coleman MK, Mushegian A Detection of biochemical pathways by probabilistic matching of phyletic vectors PLoS ONE 2009,4 e5326 "</p> <p>" McNairn AJ, Gerton JL Intersection of ChIP and FLIP, genomic methods to study the dynamics of the cohesin proteins Chromosome Res 2009,17 155-163 "</p> <p>" Magill G, Gallagher VF, Neaves WB Ontological and Ethical Implication of Direct Nuclear Reprogramming Kennedy Institute of Ethics Journal 2009,19 23-32 "</p> <p>" Mosley AL, Florens L, Wen Z, Washburn MP A label free quantitative proteomic analysis of the Saccharomyces cerevisiae nucleus J Proteomics 2009,72 110-120 "</p> <p>" Mosley AL, Pattenden SG, Carey M, Venkatesh S, Gilmore JM, Florens L, Workman JL, Washburn MP Rtr1 is a CTD phosphatase that regulates RNA polymerase II during the transition from serine 5 to serine 2 phosphorylation Mol Cell 2009,34 168-178 "</p> <p>" Nakanishi S, Lee JS, Gardner KE, Gardner JM, Takahashi YH, Chandrasekharan MB, Sun ZW, Osley MA, Strahl BD, Jaspersen SL, Shilatifard A Histone H2BK123 monoubiquitination is the critical determinant for H3K4 and H3K79 trimethylation by COMPASS and Dot1 J Cell Biol 2009,186 371-377 "</p> <p>" Oza P, Jaspersen SL, Miele A, Dekker J, Peterson CL Mechanisms that regulate localization of a DNA double-strand break to the nuclear periphery Genes Dev 2009,23 912-927 "</p> <p>" Patel AB, Gibson WT, Gibson MC, Nagpal R Modeling and inferring cleavage patterns in proliferating epithelia PLoS Comput Biol 2009,5 e1000412 "</p> <p>" Resnick TD, Dej KJ, Xiang Y, Haw ley RS, Ahn C, Orr-Weaver TL Mutations in the chromosomal passenger complex and the condensin complex differentially affect synaptonemal complex disassembly and metaphase I configuration in Drosophila female meiosis Genetics 2009,181 875-887 "</p> <p>" Rubinstein B, Fournier MF, Jacobson K, Verkhovsky AB, Mogilner A Actin-myosin viscoelastic flow in the keratocyte lamellipod Biophys J 2009,97 1853-1863 "</p> <p>" Rubinstein B, Larripa K, Sommi P, Mogilner A The elasticity of motor-microtubule bundles and shape of the mitotic spindle Phys Biol 2009,6 16005 "</p> <p>" Sardi ME, Florens L, Washburn MP Evaluation of clustering algorithms for protein complex and protein interaction network assembly J Proteome Res 2009,8 2944-2952 "</p> <p>" Sardi ME, Gilmore JM, Carrozza MJ, Li B, Workman JL, Florens L, Washburn MP Determining protein complex connectivity using a probabilistic deletion network derived from quantitative proteomics PLoS One 2009,4 e7310 "</p> <p>" Sarthy J, Bae NS, Scrafford J, Baumann P Human RAP1 inhibits non-homologous end joining at telomeres EMBO J 2009,28 3390-3399 "</p> <p>" Schulze JM, Jackson J, Nakanishi S, Gardner JM, Hentrich T, Haug J, Johnston M, Jaspersen SL, Kobor MS, Shilatifard A Linking cell cycle to histone modifications SBF and H2B monoubiquitination machinery and cell-cycle regulation of H3K79 dimethylation Mol Cell 2009,35 626-641 "</p> <p>" Shelton C, Kocherlakota KS, Zhuang S, Abmayr SM The immunoglobulin superfamily member Hbs functions redundantly with Sns in interactions between founder and fusion-competent myoblasts Development 2009,136 1159-1168 "</p> <p>" Shen R, Weng C, Yu J, Xie T eIF4A controls germline stem cell self-renewal by directly inhibiting BAM function in the Drosophila ovary Proc Natl Acad Sci U S A 2009,106 11623-11628 "</p> <p>" Shi M, Vivian CJ, Lee KJ, Ge C, Morotomi-Yano K, Manzi C, Bock F, Sato S, Tomomori-Sato C, Zhu R, Haug JS, Swanson SK, Washburn MP, Chen DJ, Chen BP, Villunger A, Florens L, Du C DNA-PKcs-PIDDosome a nuclear caspase-2-activating complex with role in G2/M checkpoint maintenance Cell 2009,136 508-520 "</p> <p>" Skaar JR, Richard DJ, Saraf A, Toschi A, Bolderson E, Florens L, Washburn MP, Khanna KK, Pagano M INTS3 controls the hSSB1-mediated DNA damage response J Cell Biol 2009,187 25-32 "</p>



Identifier	Return Reference	Explanation
FORM 990,PART III,LINE 4		<p>" Slaughter BD, Das A, Schwartz JW, Rubinstein B, Li R Dual modes of cdc42 recycling fine-tune polarized morphogenesis Dev Cell 2009,17 823-835 " Takahashi H, Martin-Brown S, Washburn MP, Florens L, Conaway JW, Conaway RC Proteomics reveals a physical and functional link between hepatocyte nuclear factor 4{alpha} and TFIIID J Biol Chem 2009,284 32405-32412 " Takahashi YH, Lee JS, Swanson SK, Saraf A, Florens L, Washburn MP, Trievel RC, Shilatifard A Regulation of H3K4 Trimethylation via Cps40 (Spp1) of COMPASS is monoubiquitination independent implication for a Phe/Tyr switch by the catalytic domain of Set1 Mol Cell Biol 2009,29 3478-3486 " Trainor PA, Dixon J, Dixon MJ Treacher Collins syndrome etiology, pathogenesis and prevention Eur J Hum Genet 2009,17 275-283 " Tsoy O, Ravcheev D, Mushegian A Comparative genomics of ethanolamine utilization J Bacteriol 2009,191 7157-7164 " Wai SC, Gerber SA, Li R Multisite phosphorylation of the guanine nucleotide exchange factor Cdc24 during yeast cell polarization PLoS One 2009,4 e6563 " Wang P, Lin C, Smith ER, Guo H, Sanderson BW, Wu M, Gogol M, Alexander T, Seidel C, Wiedemann LM, Ge K, Krumlauf R, Shilatifard A Global analysis of H3K4 methylation defines MLL family member targets and points to a role for MLL1-mediated H3K4 methylation in the regulation of transcriptional initiation by RNA polymerase II Mol Cell Biol 2009,29 6074-6085 " Weake VM, Swanson SK, Mushegian A, Florens L, Washburn MP, Abmayr SM, Workman JL A novel histone fold domain-containing protein that replaces TAF6 in Drosophila SAGA is required for SAGA-dependent gene expression Genes Dev 2009,23 2818-2823 " Wiegraebe W, Xie Y, Yin T, Stark D, Perko K, Alexander R, Schwartz J, He XC, Li L Two-photon microscopy and spectral detection for ex vivo imaging of individual stem cells Nature Protocols in Protocols Network 2009 Available at <a href="http://www.natureprotocols.com/2009/02/19/two-photon_microscopy_and_spectral_ph">http://www.natureprotocols.com/2009/02/19/two-photon_microscopy_and_spectral_ph</a> Accessed September 28, 2009 " Xie Y, Yin T, Wiegraebe W, He XC, Miller D, Stark D, Perko K, Alexander R, Schwartz J, Grindley JC, Park J, Haug JS, Wunderlich JP, Li H, Zhang S, Johnson T, Feldman RA, Li L Detection of functional haematopoietic stem cell niche using real-time imaging Nature 2009,457 97-101 " Zhang Y, Wen Z, Washburn MP, Florens L Effect of dynamic exclusion duration on spectral count based quantitative proteomics Anal Chem 2009,81 6317-6326 " Zhuang S, Shao H, Guo F, Trimble R, Pearce E, Abmayr SM Sns and Kirre, the Drosophila orthologs of Neph1 and Neph1, direct adhesion, fusion and formation of a slit diaphragm-like structure in insect nephrocytes Development 2009,136 2335-2344 Reviews, Commentaries or Chapters " Alexander T, Nolte C, Krumlauf R Hox Alexander T, Nolte C, Krumlauf R Hox genes and segmentation of the hindbrain and axial skeleton Annu Rev Cell Dev Biol 2009,25 431-456 " Baumann P Journal club A molecular biologist explores ways to revolutionize agriculture Nature 2009,462 547 " Berger SL, Kouzarides T, Shiekhatter R, Shilatifard A An operational definition of epigenetics Genes Dev 2009,23 781-783 " Conaway RC, Conaway JW Mediator comes out from the shadows Structure 2009,17 485-486 " Conaway RC, Conaway JW The INO80 chromatin remodeling complex in transcription, replication and repair Trends Biochem Sci 2009,34 71-77 " Gibson WT, Gibson MC Cell topology, geometry, and morphogenesis in proliferating epithelia Curr Top Dev Biol 2009,89 87-114 " Hall HE, Hawley RS The hows and Ys of genome integrity Cell 2009,138 830-832 " Hawley RS A direct measurement of crossingover in human orophase oocytes F1000 Biol Rpts [serial online] 2009,1 86 Available at <a href="http://F1000.com/Reports/Biology/content/1/86">http://F1000.com/Reports/Biology/content/1/86</a> , Accessed November 16, 2009 " Hawley RS, Gilliland WD Homologue pairing getting it right Nat Cell Biol 2009,11 917-918 " Hawley RS Review of "Life Illuminated Selected Papers from Cold Spring Harbor", Volume 2, 1972-1994, edited by J Witkowski et al Q Rev Biol 2009,84 183 " Herz HM, Nakanishi S, Shilatifard A The curious case of bivalent marks Dev Cell 2009,17 301-303 " Hughes SE, Hawley RS Heterochromatin a rapidly evolving species barrier PLoS Biol 2009,7 e1000233 " Imura T, Denans N, Pourquie O Establishment of Hox vertebral identities in the embryonic spine precursors Curr Top Dev Biol 2009,88 201-234 " Jackson J, Shilatifard A Global proteomic analysis of Saccharomyces cerevisiae identifies molecular pathways of histone modifications Methods Mol Biol 2009,548 175-186 " Jaspersen SL, Hawley RS Pushing and pulling microtubules mediate meiotic pairing and synapsis Cell 2009,139 861-863 " Korfali N, Fairley EA, Swanson SK, Florens L, Schirmer EC Use of sequential chemical extractions to purify nuclear membrane proteins for proteomics identification Methods Mol Biol 2009,528 201-225 " Kulesa PM, Lefcort F, Kasemeier-Kulesa JC The migration of autonomic precursor cells in the embryo Auton Neurosci 2009,151 3-9 " Lawrence C, Sanders GE, Varga ZM, Baumann DP, Freeman A, Baur B, Francis M Regulatory compliance and the zebrafish Zebrafish 2009,6 453-456 " Li R, Wedlich-Soldner R Bem1 complexes and the complexity of yeast cell polarization Curr Biol 2009,19 R195-R195 " Liu Y, Conaway JW When transcription meets recombination a lesson from the human RECQ protein complexes F1000 Biol Rpts [serial online] 2009,1 76 Available at <a href="http://f1000biology.com/reports/103410/b1-76/">http://f1000biology.com/reports/103410/b1-76/</a>, Accessed October 14, 2009 " Parrish M, Nolte C, Krumlauf R Hox genes expression In L Squire, ed New Encyclopedia of Neuroscience 4th ed Academic Press, 2009 1221-1231 " Ross J, Li L HSC mobilization new incites and insights Blood 2009,114 1283-1284 " Sakai D, Trainor PA Treacher Collins syndrome unmasking the role of Tcof1/treacle Int J Biochem Cell Biol 2009,41 1229-1232 " Slaughter BD, Smith SE, Li R Symmetry breaking in the life cycle of the budding yeast Cold Spring Harbor Perspect Biol 2009,1 a003384 " Smith E, Shilatifard A Developmental biology Histone cross-talk in stem cells Science 2009,323 221-222 " Smith KT, Workman JL Histone deacetylase inhibitors anticancer compounds Int J Biochem Cell Biol 2009,41 21-25 " Smith KT, Workman JL Introducing the acetylome Nat Biotechnol 2009,27 917-919 " Swanson SK, Florens L, Washburn MP Generation and analysis of multidimensional protein identification technology datasets Methods Mol Biol 2009,492 1-20 " Trainor P Facial birth defects unmasked Australas Sci 2009 29-32 " Trievel RC, Shilatifard A WDR5, a complexed protein Nat Struct Mol Biol 2009,16 678-680 " Tmpel S, Wiedemann LM, Krumlauf R Hox genes and segmentation of the vertebrate hindbrain Curr Top Dev Biol 2009/08/05 ed, 2009,88 103-137 " Wang J, Rodova M, Gardner BM, Lu Q, Trainor PA, Yost JG Wnt/?-catenin signaling plays an essential role in bone sialoprotein-elicited osteoblast differentiation and mineralization Bone 2009,44 S158-S159</p>

Identifier	Return Reference	Explanation
FORM 990,PART III,LINE 4		<p>" Weake VM, Workman JL Histone Ubiquitination In RA Bradshaw , and EA Dennis, eds Handbook of Cell Signaling 2nd ed Oxford Academic Press, 2009 2449-2460 " Weake VM, Workman JL Hit and run X marks the spot! Nat Struct Mol Biol 2009,16 801-803 " Xie T Stem cell in the adult Drosophila hindgut just a sleeping beauty Cell Stem Cell 2009,5 227-228 " Xie T, Song X, Jin Z, Pan L, Weng C, Chen S, Zhang N Interactions between Stem Cells and Their Niche in the Drosophila Ovary Abstracts of papers presented at the LXXIII Cold Spring Harbor Symposium on Quantitative Biology Control &amp; Regulation of Stem Cells May 28-June 2, 2008 Cold Spring Harbor, N Y Cold Spring Harbor Laboratory 2009,72 " Yin T, Xie Y, Li L Visualize eHPCs in different zones Blood 2009,114 230-231 " Zhang N, Xie T Extrinsic and intrinsic control of germline stem cell regulation in the Drosophila ovary In VK Rajasekhar, and MC Vemuri, eds Regulatory networks in stem cells 1st ed New York Humana, 2009 155-163 Book " Pourquoi O, ed Hox Genes, 1st ed San Diego, Academic Press 2009 Competitive Research Grant Funding &amp; Research Awards &amp; Distinctions The ability of Stowers Institute scientists to receive increasing numbers of competitively awarded research grants attests to the high level of research productivity present at the Institute During 2009, Stowers scientists worked with the support of 24 grants and fellowships from the National Institutes of Health, one grant and one fellowship from the American Cancer Society, three fellowships from The Leukemia and Lymphoma Society, one award from the Klingenstein Fund, one award from the McKnight Foundation, one grant from the National Science Foundation, one grant from the Greater Kansas City Community Foundation, two Hudson Prizes from the M R and Evelyn Hudson Foundation, two March of Dimes awards, one Pew Scholar Award, one award from the Burroughs Wellcome Fund, two investigator awards from the Howard Hughes Medical Institute, and one fellowship from The Jane Coffin Childs Memorial Fund With new and recurring grant support, the Institute is receiving more than \$8 million a year in research funding to supplement the income from its endowments Testifying to the high level of achievement taking place at the Institute are the awards and honors Institute scientists received in 2009 " Karen Smith, Ph D , Postdoctoral Research Fellow in the Workman Lab, received the American Cancer Society Cattle Barron's Ball of Lubbock Postdoctoral Fellowship, effective in January " Ron Yu, Ph D , Assistant Investigator, received two supplements to his National Institutes of Health grant, effective in June and July " Hans-Martin Herz, Ph D , Postdoctoral Research Fellow in the Shilatifard Lab, was appointed a Fellow of The Jane Coffin Childs Memorial Fund for Medical Research, effective in July " Sue Jaspersen, Ph D , Assistant Investigator, received the Hudson Prize from the M R and Evelyn Hudson Foundation, effective in July " Shima Nakanishi, Ph D , Postdoctoral Research Fellow in the Shilatifard Lab, received a Leukemia and Lymphoma Society Fellowship, effective in July " Kausik Si, Ph D , Assistant Investigator, received a McKnight Scholar Award from The McKnight Endowment Fund for Neuroscience, effective in July " Paul Kulesa, Ph D , Director of Imaging, was a sub-recipient on a National Science Foundation grant from Montana State University, effective in August " Peter Baumann, Ph D , Associate Investigator, was named a Howard Hughes Medical Institute Early Career Scientist, effective in September " Linheng Li, Ph D , Investigator, received a National Institutes of Health grant, effective in September " Paul Trainor, Ph D , Associate Investigator, was a sub-recipient on a National Institutes of Health grant from Cincinnati Children's Hospital, effective in September " Susan Abmayr, Ph D , Associate Investigator, and Jerry Workman, Ph D , Investigator, received a supplement to Jerry Workman's National Institutes of Health grant, effective in September Cooperation Agreements and Collaborations The Stowers Institute continued collaborations in 2009 with hospitals in Kansas City (Children's Mercy and St Luke's) and in Boston (Massachusetts General Hospital) The Institute also collaborates with University of Missouri at Kansas City, University of Kansas, Howard Hughes Medical Institute, Harvard University, Harvard Stem Cell Institute, Harvard Medical School, Broad Institute, and Columbia University, most of which are associated with teaching and research hospitals Additional collaborations occurred in 2009 with University of California-Berkeley, University of California-Davis, University of California-Los Angeles, University of California-San Diego, University of Maryland, University of Michigan, University of New Orleans, University of North Carolina, University of Pennsylvania, University of Texas Southwestern Medical Center, University of Texas-San Antonio, University of Washington, California Institute of Technology, Case Western Reserve University, Cincinnati Children's Hospital Medical Center, Dana Farber Cancer Institute, Dartmouth College, Duke University, Humboldt State University, Johns Hopkins University, Massachusetts Institute of Technology, Montana State University, National Institutes of Health, Northwestern University, Oregon State University, Pennsylvania State University, Rockefeller University, Scripps Research Institute, Simon Fraser University, Vanderbilt University, Washington University in St Louis, Yale University, Ernest Orlando Lawrence Berkeley National Laboratory, Wistar Institute, University of Alberta, University of British Columbia, University of Dundee, University of Manchester, Aravind Eye Hospital, Cancer Research UK, Chinese Academy of Sciences, Ecole Polytechnique Federale de Lausanne, European Molecular Biology Laboratory, Gurdon Institute, Innsbruck Medical University, Institut Catalana de Recerca, Karolinska Institutet, Max Planck Institute, MRC Human Genetics Unit, Moscow State University, Open University, Shanghai Jiao Tong University, Shanghai Rui Jin Hospital</p>

Identifier	Return Reference	Explanation
SUPPLEMENTAL INFORMATION		<p>Independent Research Program Leaders Laboratories Individual scientists at the Stow ers Institute specialize in the study of one or more particular genes, each of which may cause or have influence in various kinds of disease A comprehensive list of research leaders follow s " Robert Krumlauf, Ph D , Scientific Director and Investigator, joined the Stow ers Institute in 2000 from England's National Institute for Medical Research, The Ridgew ay, Mill Hill, London, w here he was head of the Division of Developmental Neurobiology Dr Krumlauf received a Ph D in developmental biology from Ohio State University Research Focus Analysis of molecular pathw ays that regulate how the mammalian head, brain and nervous system are built, using a variety of vertebrate model systems " Susan Abmayr, Ph D , Associate Investigator, joined the Stow ers Institute in 2003 from the Pennsylvania State University w here she served as Associate Professor of Molecular Genetics She earned a Ph D in biochemistry and molecular biology from the Rockefeller University and completed postdoctoral training in the Department of Biochemistry and Molecular Biology at Harvard University under the direction of Professor Tom Maniatis Research Focus Molecular genetics of cell fate specification and differentiation in Drosophila, using the embryonic development of the musculature as a model system" Peter Baumann, Ph D , Associate Investigator and How ard Hughes Medical Institute Early Career Investigator, joined the Stow ers Institute in 2002 after completing a How ard Hughes Medical Institute postdoctoral fellow ship in the laboratory of Dr Thomas R Cech at the University of Colorado-Boulder Dr Baumann received a Ph D in biochemistry from the Imperial Cancer Research Fund and University College, London Research Focus Functional analysis of telomeres and their roles in cellular immortality and cancer " Marco Blanchette, Ph D , Assistant Investigator, joined the Stow ers Institute in 2006 from a postdoctoral position w ith Dr Donald C Rio at the University of California-Berkeley w here he was recipient of a Human Frontier Long-Term Fellow ship Dr Blanchette received a Ph D degree in microbiology from the Universit de Sherbrooke, Canada Research Focus Functional genomic analysis of the mechanisms controlling alternative pre-mRNA splicing " Joan Conaw ay, Ph D , Investigator, joined the Stow ers Institute in 2001 from the Oklahoma Medical Research Foundation w here she was an Associate Investigator of the How ard Hughes Medical Institute and interim head of the program in Molecular and Cell Biology Dr Conaw ay received her doctorate in cell biology from Stanford University School of Medicine Research Focus Analysis of the molecular mechanism and regulation of gene transcription " Ronald Conaw ay, Ph D , Investigator, joined the Stow ers Institute in 2001 from the Oklahoma Medical Research Foundation w here he was holder of the Chapman Chair in Medical Research Dr Conaw ay received his Ph D in biochemistry from Stanford University School of Medicine Research Focus Analysis of the molecular mechanism and regulation of gene transcription " Chad Cow an, Ph D , Assistant Investigator, joined the Stow ers Institute in 2006 from a postdoctoral fellow ship in the laboratory of Dr Douglas Melton in the Department of Molecular and Cellular Biology at Harvard University He earned a Ph D in Cell Regulation from University of Texas Southw estern Medical Center Research Focus Understanding the contribution of environmental and genetic factors in the development of disease " Kevin Eggan, Ph D , Assistant Investigator, joined the Stow ers Institute in 2005 from a junior fellow ship at Harvard University He received a Ph D in Biology from the Massachusetts Institute of Technology Research Focus How variation in chromatin structure regulates developmental potency, cell fate, and gene expression " Jennifer Gerton, Ph D , Associate Investigator, joined the Stow ers Institute in 2002 from a postdoctoral fellow ship in the laboratory of Dr Joseph DeRisi in the Department of Biochemistry and Biophysics at the University of California-San Francisco Dr Gerton received a Ph D in microbiology and immunology from Stanford University Research Focus Genomic and genetic analysis of chromosome segregation and chromosome dynamics " R Scott Haw ley, Ph D , Investigator, joined the Stow ers Institute in 2001 from the University of California-Davis w here he was a professor of genetics in the Molecular and Cellular Biology section Dr Haw ley earned a Ph D in genetics from the University of Washington and completed postdoctoral training as a Helen Hay Whitney Fellow at the Institute for Cancer Research in Philadelphia Research Focus Investigation of mechanisms that influence how chromosomes pair and segregate during meiosis using Drosophila as an experimental system" Sue Jaspersen, Ph D , Assistant Investigator, joined the Stow ers Institute in 2005 from the laboratory of Dr Mark Winey at the University of Colorado-Boulder w here she was a Keck Foundation Fellow , a Helen Hay Whitney Fellow , and the recipient of a Leukemia &amp; Lymphoma Society Career Development Award Dr Jaspersen holds a Ph D in biochemistry from the University of California-San Francisco</p>

Identifier	Return Reference	Explanation
SUPPLEMENTAL INFORMATION		<p>Research Focus Inner nuclear membrane protein localization and role in chromosome positioning and segregation " Linheng Li, Ph D , Investigator, joined the Stow ers Institute in 2000 from the University of Washington Medical Center w here he held a faculty appointment after completing postdoctoral training in the laboratory directed by Dr Leroy Hood Dr Li earned his Ph D in molecular and cellular biology from New York University Medical School under the mentoring of Dr Edw ard Ziff Research Focus Investigation of molecular and genetic pathw ays controlling adult stem cell development in the hematopoietic and intestinal systems using transgenic and gene targeting animal model approaches " Rong Li, Ph D , Investigator, joined the Stow ers Institute in 2005 from the Department of Cell Biology at Harvard Medical School w here she served as an Associate Professor She earned a Ph D in cell biology at the University of California-San Francisco with Dr Andrew Murray and held a Damon Runyon-Walter Winchell Cancer Research Fellow ship as a postdoctoral associate with Dr David Drubin at the University of California-Berkeley Research Focus Mechanism of cell polarization and cell motility, biochemical basis of dynamics in the actin cytoskeleton, and how eukaryotic cells divide " Ho Yi Mak, Ph D , Assistant Investigator, joined the Stow ers Institute in 2006 from a Human Frontier Science Program postdoctoral fellow ship in the laboratory of Dr Gary Ruvkun at Harvard Medical School Dr Mak received a Ph D in molecular pathology from the Imperial Cancer Research Fund and University College, London Research Focus Genetic and molecular analysis on endocrine control of fat storage " Ali Shilatfard, Ph D , Investigator, joined the Stow ers Institute in 2007 from the Saint Louis University School of Medicine w here he w as a Professor of Biochemistry and Associate Director for Basic Sciences at the Saint Louis University Cancer Center Dr Shilatfard earned a Ph D in biochemistry from the University of Georgia and the University of Oklahoma School of Medicine and completed postdoctoral training as a Jane Coffin Childs Fellow at the Oklahoma Medical Research Foundation Research Focus Molecular pathw ay of leukemogenesis " Kausik Si, Ph D , Assistant Investigator, joined the Stow ers Institute in 2005 from the laboratory of Dr Eric Kandel at Columbia University Center for Neurobiology and Behavior w here he w as a Jane Coffin Childs Fellow and a Francis Goelet Fellow in Neuroscience Dr Si earned a Ph D in molecular biology from the Albert Einstein College of Medicine Research Focus Role of synaptic protein synthesis in information acquisition and memory storage " Paul Trainor, Ph D , Associate Investigator, joined the Stow ers Institute in 2001 from a research position at the National Institute for Medical Research at Mill Hill, London, w here he completed postdoctoral training Dr Trainor has a Ph D in developmental biology from Children's Medical Research Institute at the University of Sydney, Australia Research Focus Investigation of the interactions betw een distinct tissues in the body and their regulation during normal development to reveal pathw ays that regulate normal cranial and facial development " Jerry Workman, Ph D , Investigator, joined the Stow ers Institute in 2003 from the Pennsylvania State University w here he held the Paul Berg Professorship of Biochemistry and w as an Associate Investigator of the How ard Hughes Medical Institute Dr Workman earned a Ph D in cell and molecular biology from the University of Michigan and completed postdoctoral training at the Rockefeller University with Dr Bob Roeder Research Focus Study of the protein complexes that modify chromatin " Ting Xie, Ph D , Investigator, joined the Stow ers Institute in 2000 after completing a How ard Hughes Medical Institute postdoctoral fellow ship in the laboratory of Dr Allan C Spradling at the Carnegie Institution of Washington Dr Xie received his Ph D from the Joint Graduate Program in Molecular Biology and Biochemistry of Rutgers University and the University of Medicine and Dentistry of New Jersey Research Focus Genetic and molecular analysis of stem cells and germ cell development in Drosophila and mouse " C Ron Yu, Ph D , Assistant Investigator, joined the Stow ers Institute in 2005 from the laboratory of Dr Richard Axel at Columbia University Center for Neurobiology and Behavior w here he held a National Institutes of Health Mentored Research Scientist Aw ard from the National Institute of Mental Health Dr Yu earned his Ph D in molecular, cellular, and biophysical studies at Columbia University Research Focus How olfactory sensory information is detected, integrated, and processed in the brain to influence specific innate behaviors " Julia Zeitlinger, Ph D , Assistant Investigator, joined the Stow ers Institute in 2007 from the lab of Dr Richard Young at the Whitehead Institute for Biomedical Research at Massachusetts Institute of Technology w here she w as the recipient of a long-term postdoctoral fellow ship from the Human Frontier Science Program Dr Zeitlinger earned a Ph D in molecular biology from the European Molecular Biology Laboratory in Heidelberg, Germany Research Focus Analysis of the gene regulatory netw orks underlying cellular differentiation Technology Centers " Paul Kulesa, Ph D , Director of Imaging Center, joined the Stow ers Institute in 2002 after completing a Burroughs Wellcome Fund postdoctoral fellow ship in the laboratory of Dr Scott E Fraser at the California Institute of Technology Dr Kulesa received a Ph D in applied mathematics under Dr J D Murray at the University of Washington Research Focus Cell migration in development and cancer " Arcady Mushegian, Ph D , Director of Bioinformatics Center, joined the Stow ers Institute in 2001 from Akkadix Corporation in San Diego w here he led the bioinformatics program Dr Mushegian earned a doctorate in molecular biology at Moscow State University and received training at the University of Kentucky, University of Washington, and w ith Dr Eugene Koonin at the National Center for Biotechnology Information at the U S National Institutes of Health Research Focus Computational analysis of genes and proteins " Michael Washburn, Ph D , Director of Proteomics Center, joined the Stow ers Institute in 2003 from the Torrey Mesa Research Institute in San Diego w here he w as a Senior Staff Scientist in Proteomics He earned a Ph D in biochemistry and environmental toxicology from Michigan State University before completing a postdoctoral fellow ship w ith Professor John Yates, III in the Department of Molecular Biotechnology at the University of Washington Research Focus Quantitative proteomics and protein complex dynamics</p>



Part III

Identification of Related Organizations Taxable as a Partnership (Complete if the organization answered "Yes" on Form 990, Part IV, line 34 because it had one or more related organizations treated as a partnership during the tax year.)

(a) Name, address, and EIN of related organization	(b) Primary activity	(c) Legal domicile (state or foreign country)	(d) Direct controlling entity	(e) Predominant income (related, unrelated, excluded from tax under sections 512- 514)	(f) Share of total income	(g) Share of end-of-year assets	(h) Dispropportionate allocations?		(i) Code V—UBI amount in box 20 of Schedule K-1 (Form 1065)	(j) General or managing partner?	
							Yes	No		Yes	No

Part IV

Identification of Related Organizations Taxable as a Corporation or Trust (Complete if the organization answered "Yes" on Form 990, Part IV, line 34 because it had one or more related organizations treated as a corporation or trust during the tax year.)

(a) Name, address, and EIN of related organization	(b) Primary activity	(c) Legal domicile (state or foreign country)	(d) Direct controlling entity	(e) Type of entity (C corp, S corp, or trust)	(f) Share of total income	(g) Share of end-of-year assets	(h) Percentage ownership
BIOMED VALLEY DISCOVERIESINC 8333 HICKMAN MILLS DRIVE KANSAS CITY, MO64132 06-1646533	SCI DISC DVLP	DE	NA	C			

Part V

Transactions With Related Organizations (Complete if the organization answered "Yes" on Form 990, Part IV, line 34, 35, or 36.)

Note. Complete line 1 if any entity is listed in Parts II, III or IV

1

During the tax year, did the organization engage in any of the following transactions with one or more related organizations listed in Parts II-IV?

a

Receipt of (i) interest (ii) annuities (iii) royalties (iv) rent from a controlled entity

b

Gift, grant, or capital contribution to other organization(s)

c

Gift, grant, or capital contribution from other organization(s)

d

Loans or loan guarantees to or for other organization(s)

e

Loans or loan guarantees by other organization(s)

f

Sale of assets to other organization(s)

g

Purchase of assets from other organization(s)

h

Exchange of assets

i

Lease of facilities, equipment, or other assets to other organization(s)

j

Lease of facilities, equipment, or other assets from other organization(s)

k

Performance of services or membership or fundraising solicitations for other organization(s)

l

Performance of services or membership or fundraising solicitations by other organization(s)

m

Sharing of facilities, equipment, mailing lists, or other assets

n

Sharing of paid employees

o

Reimbursement paid to other organization for expenses

p

Reimbursement paid by other organization for expenses

q

Other transfer of cash or property to other organization(s)

r

Other transfer of cash or property from other organization(s)

Yes

No

1a

Yes

1b

No

1c

Yes

1d

No

1e

No

1f

Yes

1g

No

1h

No

1i

No

1j

Yes

1k

No

1l

No

1m

Yes

1n

Yes

1o

Yes

1p

Yes

1q

No

1r

No

2 If the answer to any of the above is "Yes," see the instructions for information on who must complete this line, including covered relationships and transaction thresholds

	(a) Name of other organization	(b) Transaction type(a-r)	(c) Amount involved
(1)	BIOMED VALLEY DISCOVERIESINC	A	415,575
(2)	BIOMED VALLEY DISCOVERIESINC	A	10,636
(3)	STOWERS REAL ESTATE HOLDING CORP	J	2,230,551
(4)	STOWERS REAL ESTATE HOLDING CORP	P	148,511
(5)			
(6)			

Provide the following information for each entity taxed as a partnership through which the organization conducted more than five percent of its activities (measured by total assets or gross revenue) that was not a related organization. See instructions regarding exclusion for certain investment partnerships.

(a)	(b)	(c)	(d)		(e)	(f)		(g)	(h)	
Name, address, and EIN of entity	Primary activity	Legal domicile (state or foreign country)	Are all partners section 501(c)(3) organizations?		Share of end-of-year assets	Disproportionate allocations?		Code V—UBI amount in box 20 of Schedule K-1 (Form 1065)	General or managing partner?	
			Yes	No		Yes	No		Yes	No